151
|
Wu YL, Zhao J, Hu J, Wu J, Xu Y, Yang Z, Liu Z, Jiang L, Chen J, Yu Y, Huang M, Dong X, Liu L, Feng W, Wu L, Cang S, Sun J, Xie Q, Chen HJ. 388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
152
|
Peng S, Sang T, Wang H, Guan Y, Deng Y, Wang P, Huang Z, Ye Z, Wu J. Bioinspired Anti-demineralization Enamel Coating for Orthodontics. J Dent Res 2022; 101:1620-1627. [PMID: 36271659 DOI: 10.1177/00220345221129806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
White spot lesions and enamel cracks are the 2 most prominent diseases that occur after orthodontic treatment and are caused by enamel demineralization from accumulated bacterial biofilms and/or enamel damage caused by the removal of residual adhesive after bracket debonding. Inspired by the self-assembled amelogenin nanoribbons in enamel, we developed an enamel coating with a self-assembling antimicrobial peptide, D-GL13K, to simultaneously reduce demineralization and residual adhesive. The self-assembled amphiphilic nanoribbons significantly increased the hydrophobicity of the etched enamel, which reduced the permeability of the coated enamel surfaces as desired. The antimicrobial activity of this coating was evaluated against Streptococcus mutans by colony-forming unit counting and live/dead assays. The anti-demineralization effect was demonstrated by the reduced demineralization depth analyzed by optical coherence tomography and the increased Vickers hardness. The coatings did not reduce the shear bond strength but significantly reduced the adhesive remnant index score. This bioinspired enamel coating may provide a new strategy for preventing white spot lesions and enamel cracks after orthodontic treatment.
Collapse
|
153
|
He YL, Zou YW, Hu YJ, Wu J, Zhang W, Yu WJ, Li YJ, Jiang YX. [Clinicopathological features and diagnosis of pericytic tumors of the kidney]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2022; 51:987-992. [PMID: 36207911 DOI: 10.3760/cma.j.cn112151-20220211-00093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To investigate the clinicopathologic features,diagnosis and prognosis of pericytic tumor of the kidney. Methods: Three cases of pericytic tumor of the kidney (two cases were diagnosed as glomangiomyomas and one case as pericytic tumor,unclassified) were collected from the affiliated Hospital of Qingdao University between January 2014 to May 2021; the clinical and morphologic features, immunohistochemical and molecular characteristics were analyzed and the relevant literature was reviewed. Results: The three patients included one male and two females, with ages ranging from 21 to 70 years. In two patients the tumors were detected incidentally at physical examination and one patient presented with low back discomfort. Imaging showed a rounded nodular soft tissue density shadow in renal parenchyma, and enhancement scan showed uneven delayed enhancement. Grossly, two tumors were located in the renal hilum and one in the renal parenchyma; all were nodular. The tumors were measured in size from 1.6 cm to 5.1 cm (mean 4.1 cm) and showed gray or gray-red cut surface. Histologic examination showed the tumor cells were arranged in solid sheets or small nodules, closely related to vascular wall. Tumor cells were mostly epithelial-like with abundant cytoplasm, light eosinophilia, obscure boundary and round nuclei with visible nucleoli. Vague bundles and fascicular arrangements of smooth muscle component were noted in some areas, with transition of both components. There was no necrosis. By immunohistochemistry, the tumor cells strongly and diffusely expressed vimentin, SMA and collagen Ⅳ, two cases expressed CD34, all three cases expressed PDGFRB to varying extent, and the Ki-67 index was 2%-3%. PCR tests showed absent K-RAS, BRAF V600E gene mutation in all three cases. PDGFRB mutations in exons 3 and 18, respectively were found in two of the three cases by high-throughput sequencing, and no NOTCH 1/2/3 gene fusions were found in any of them. Follow-up information (range: 6-92 months) showed no evidence of local recurrence or distant metastasis in all three patients. Conclusions: Pericytic tumor of the kidney is a rare mesenchymal tumor originating in the kidney with differentiation to smooth muscle, most commonly glomus tumor. The mild pleomorphism, close relationship with vascular wall and spindled smooth muscle components suggest the diagnosis of the tumor. Expression of both epithelial and muscle-associated markers aids the diagnosis. PDGFRB gene mutations may have an important role in the development of this tumor. Most patients have a good prognosis, and a few cases have malignant biological behavior.
Collapse
|
154
|
Wu J, Moser D. Cognitive impairment and low health literacy are associated with poor health outcomes in patients with heart failure. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Cognitive impairment and low health literacy are prevalent in patients with heart failure (HF). Low health literacy is associated with poor health outcomes, such as frequent re-hospitalizations and increased mortality. Little is known about the relationships among cognitive impairment, health literacy, and health outcomes (HF rehospitalization and cardiac death).
Objective
To explore the associations among cognitive impairment, health literacy, and cardiac event-free survival in patients with HF.
Methods
This was a longitudinal study of 614 rural patients with HF (male 59%, age 66±13 NYHA class III/IV: 35%). Cognitive function was measured using the Mini-Cog test. Health literacy was measured by the Short Test of Functional Health Literacy in Adults. HF hospitalizations and cardiac mortality were followed at least 2 years and obtained by patient interview, medical record review, and death certificate review. Chi-squares, t-tests, ANOVA, Kaplan-Meier with log rank tests, logistic and Cox regressions were used for data analysis.
Results
Two hundred and seven patients (34%) had cognitive impairment. Compared to those without cognitive impairment, patients with cognitive impairment were 2.77 times more likely to have low health literacy (P<0.001). Patients were divided into 4 groups based on cognitive impairment or not and adequate/low health literacy: (1) No cognitive impairment with adequate health literacy; (2) cognitive impairment with adequate health literacy; (3) no cognitive impairment with low health literacy; and (4) cognitive impairment with low health literacy. Both cognitive impairment and health literacy independently predicted cardiac event-free survival. Cardiac event-free survival was worst in those with both cognitive impairment and low health literacy compared to patients in any of the other three groups. Patients with cognitive impairment and low health literacy had 3.5 times higher risk of a cardiac event compared to those without cognitive impairment or low health literacy (P<0.001, Figure). Age, income, angiotensin converting enzyme inhibitor use, beta-blocker use, New York Heart Association functional class, left ventricular ejection fraction, BNP level were significantly different among the four cognitive and literacy groups.
Conclusion
Patients with cognitive impairment with low health literacy were at high risk of experiencing a cardiac event. Interventions need to be developed to target high risk patients with cognitive impairment and low health literacy, such as older, low-income patients, to alleviate poor outcomes in patients with HF.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): NIH/NHLBI
Collapse
|
155
|
Wu J, Nadarajah R, Nakao Y, Nakao K, Wilkinson C, Raveendra K, Mamas MA, Camm AJ, Gale CP. Temporal trends and patterns in atrial fibrillation incidence: a population-based study of 3.4 million individuals. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide; confers an increased risk of adverse outcomes and once diagnosed most patients will require lifelong-treatment. Population-based studies of AF incidence are needed to inform health-service planning. However, few reports refer to a standard population and estimates of incidence in high income countries vary by over 12-fold.
Purpose
We aimed to assess trends in the crude and standardised atrial fibrillation incidence by sex, age, socioeconomic status and region in a large general population cohort from England. We also investigated the comorbidity profile of patients over almost two decades.
Methods
We used linked primary and secondary electronic health records of 3.4 million individuals from the Clinical Practice Research Datalink (CPRD). The CPRD database contains anonymised patient data from approximately 7% of the UK population and is broadly representative in terms of age, sex, and ethnicity. Eligible patients aged 16 years and older contributed data between Jan 1 1998 and Dec 31 2017. We defined incident AF diagnosis as the first record of AF in primary care or hospital admission records from any diagnostic position. For incidence calculations, we excluded all individuals who had a diagnosis of AF before the study start date, or within the first 12 months of registration with their general practice. For patients with incident AF, we extracted baseline characteristics, comorbidities, socioeconomic status and geographic region. We calculated standardised rates by applying direct age and sex standardisation to the 2013 European Standard Population. We inferred crude rates by applying year-specific, age-specific and sex-specific incidence to UK census mid-year population estimates.
Results
From 1998 to 2017 AF incidence (standardised by age and sex) increased by 30% (from 247 to 322 per 100,000 person-years; adjusted incidence ratio [IRR] 1.30, 95% CI 1.27–1.33) (Figure 1). Absolute number of incident AF increased by 72% (from 117,880 in 1998 to 202,333 in 2017), due to an increasing number of older people. Comorbidity burden at diagnosis of AF increased (2.58 [SD 1.83] vs 3.74 [2.29] conditions; adjusted difference 1.26, 95% CI 1.14–1.39). Age-standardised incidence was higher in men than women (IRR 1.49; 95% CI 1.46–1.52), and men were younger at diagnosis (adjusted difference 5.53 years; 95% CI 5.36–5.69). Socioeconomically deprived individuals had more comorbidities and were more likely to develop AF than the most affluent individuals (IRR 1.20; 95% CI 1.15–1.24). Over time, the age of AF diagnosis declined disproportionately in the most deprived individuals (Figure 2).
Conclusion
In England AF incidence has increased, and the socioeconomic gradient in age at diagnosis and comorbidity burden widened. This changing burden of AF requires policy-based interventions to prevent associated morbidity and mortality.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): British Heart Foundation, National Institute of Health Research
Collapse
|
156
|
Feng P, Wu J, Ren Y, Zhang L, Cao J, Yang L. Early pregnancy regulates the expression of prolactin and its receptor in the thymus, the liver, the spleen and lymph nodes in sheep. Domest Anim Endocrinol 2022; 81:106731. [PMID: 35635981 DOI: 10.1016/j.domaniend.2022.106731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 04/28/2022] [Accepted: 04/29/2022] [Indexed: 11/17/2022]
Abstract
As a pituitary hormone, prolactin (PRL) is also synthesized by immune system cells, and exerts its effects on the immune system by binding to its receptor (PRLR) via endocrine and paracrine/autocrine pathways. The immune organs adapt to the presence of fetal alloantigens during pregnancy, and the immune system is composed of primary organs and secondary organs. The objective of this study is to analyze the effects of early pregnancy on expression of PRL and PRLR in maternal immune organs in sheep. In this study, the thymus, lymph node, the spleen and the liver were sampled at day 16 of the estrous cycle, and at days 13, 16, and 25 of pregnancy in ewes. Expression of PRL and PRLR was analyzed through quantitative real-time PCR, Western blot and immunohistochemistry. Our data showed that there were an upregulation of PRL and PRLR in the thymus, lymph node and the spleen, and a downregulation in the liver during early pregnancy in ewes. In conclusion, it is reported for the first time that early pregnancy has tissue specific effects on expression of PRL isoform and PRLR isoform in the thymus, lymph node, the spleen and the liver, which may be owing to these organs exerting different functions during early pregnancy, and necessary for the successful pregnancy in sheep.
Collapse
|
157
|
Chen L, Li W, Fang K, Liu S, Wu J, Luo J, Tyler R, Zhang S. OQL036 topical gel inhibits the skin toxicity associated with 5-fluorouracil/capecitabine: results from in vitro and in vivo preclinical studies. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01006-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
158
|
Wang J, Buchman C, Seetharaman J, Miller D, Huber A, Wu J, Chai S, Garcia-Maldonado E, Wright C, Chenge J, Chen T. Develop selective inhibitors of drug-metabolizing enzymes CYP3A4/5 to improve cancer drug efficacy and reduce drug toxicity and resistance. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)01092-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
159
|
Wu J, Chen YZ, Wang Y. [Current situation and reflection of clinical trials in the field of burn medicine in China]. ZHONGHUA SHAO SHANG YU CHUANG MIAN XIU FU ZA ZHI 2022; 38:799-804. [PMID: 36177582 DOI: 10.3760/cma.j.cn501120-20210909-00309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Clinical trials are of great significance in formulating guidelines or consensus for the diagnosis and treatment of burns. However, the innate advantages of clinical trials in the field of burn medicine in China have not been translated into evidence-based medical data. Our research group counted the literature published in major academic journals in the field of burn medicine at home and abroad from 2010 to 2020 in Chinese and English databases, and found that the number and proportion of clinical trials in the field of burn medicine published in Chinese journals were generally lower than those in English journals. Moreover, the number and proportion of clinical trials in the field of burn medicine published in Chinese journals were lower than those in the field of critical care medicine. On this basis, our research group statistically analyzed the registration status of clinical trials in the field of burn medicine from 2010 to 2020, and found that the registration volume and completion volume of clinical trials in the field of burn medicine in China were not only lower than those in the field of burn medicine in the United States, but also lower than those in the field of critical care medicine in China. The reasons for insufficient clinical trials in the field of burn medicine may be the decrease in the incidence of burns, the decrease in the number of burn specialists and their low income, and the lack of burn research talents. It is necessary for China to integrate the advantages of clinical resources in the field of burn medicine, strengthen clinical trial research, and improve the discourse power in the international community.
Collapse
|
160
|
Wu J, Yang QY, Chen TY, Wang Z. [Extranodal NK/T-cell Lymphoma, nasal type with a high content of epithelioid histocyte: report of two cases]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2022; 51:893-895. [PMID: 36097910 DOI: 10.3760/cma.j.cn112151-20220113-00028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
|
161
|
Mar S, Kim S, Silva J, Wu J. Evaluation of a Weight Management Program for Kidney Pre-Transplant Patients. J Acad Nutr Diet 2022. [DOI: 10.1016/j.jand.2022.06.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
162
|
Zhao Y, Chen G, Li X, Wu J, Chang B, Hu S, Yang S, Liu Y, Wang N, Huang Y, Zhang L. 1029P Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: An open-label, multi-center phase II trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
163
|
Armstrong A, Sartor O, Saad F, Czernin J, Shore N, Kendi A, Beer T, Vaishampayan N, El-Haddad G, Wu J, Mirante O, Morris M. 1372P Association between prostate-specific antigen decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer in the VISION trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1504] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
164
|
Zhao J, Wu J, Cui J, Wang L, Sun M, Gao B, Ma Z, Liu Y, Wang Z, Li X, Li H, Zhang J, Sun J, Fei C, Wu YL. EP08.01-071 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
165
|
Martin Jimenez M, Lim E, Chavez Mac Gregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz F, Safin R, Kim SB, Schem C, Montero A, Khan S, Bandyopadhyay R, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno P, Sohn J. 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
166
|
Lu J, Wu J, Lou Y, Wang H, Zhong H, Chu T, Han B. EP16.01-032 Guiding Monotherapy with Docetaxel or Atezolizumab via the Tumour Mutation Index in Non-small Cell Lung Cancer Patients. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
167
|
Yang Y, Jin L, Rao N, Gong C, Li S, Li Y, Wu J, Zhao J, Ding L, Liu Q. 192P A phase II single-arm clinical study of neoadjuvant treatment with pegylated liposomal doxorubicin (PLD) plus cyclophosphamide (C) combined with trastuzumab (H) and pertuzumab (P) in HER2-positive (HER2+) breast cancer (BC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
168
|
Abdallah MS, Aboona BE, Adam J, Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal I, Aggarwal MM, Ahammed Z, Alekseev I, Anderson DM, Aparin A, Aschenauer EC, Ashraf MU, Atetalla FG, Attri A, Averichev GS, Bairathi V, Baker W, Ball Cap JG, Barish K, Behera A, Bellwied R, Bhagat P, Bhasin A, Bielcik J, Bielcikova J, Bordyuzhin IG, Brandenburg JD, Brandin AV, Bunzarov I, Cai XZ, Caines H, Calderón de la Barca Sánchez M, Cebra D, Chakaberia I, Chaloupka P, Chan BK, Chang FH, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chattopadhyay S, Chen D, Chen J, Chen JH, Chen X, Chen Z, Cheng J, Chevalier M, Choudhury S, Christie W, Chu X, Crawford HJ, Csanád M, Daugherity M, Dedovich TG, Deppner IM, Derevschikov AA, Dhamija A, Di Carlo L, Didenko L, Dixit P, Dong X, Drachenberg JL, Duckworth E, Dunlop JC, Elsey N, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fawzi FM, Fazio S, Federic P, Fedorisin J, Feng CJ, Feng Y, Filip P, Finch E, Fisyak Y, Francisco A, Fu C, Fulek L, Gagliardi CA, Galatyuk T, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Gupta A, Guryn W, Hamad AI, Hamed A, Han Y, Harabasz S, Harasty MD, Harris JW, Harrison H, He S, He W, He XH, He Y, Heppelmann S, Heppelmann S, Herrmann N, Hoffman E, Holub L, Hu Y, Huang H, Huang HZ, Huang SL, Huang T, Huang X, Huang Y, Humanic TJ, Igo G, Isenhower D, Jacobs WW, Jena C, Jentsch A, Ji Y, Jia J, Jiang K, Ju X, Judd EG, Kabana S, Kabir ML, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Khyzhniak YV, Kikoła DP, Kim C, Kimelman B, Kincses D, Kisel I, Kiselev A, Knospe AG, Ko HS, Kochenda L, Kosarzewski LK, Kramarik L, Kravtsov P, Kumar L, Kumar S, Kunnawalkam Elayavalli R, Kwasizur JH, Lacey R, Lan S, Landgraf JM, Lauret J, Lebedev A, Lednicky R, Lee JH, Leung YH, Lewis N, Li C, Li C, Li W, Li X, Li Y, Liang X, Liang Y, Licenik R, Lin T, Lin Y, Lisa MA, Liu F, Liu H, Liu H, Liu P, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Longacre RS, Loyd E, Lukow NS, Luo XF, Ma L, Ma R, Ma YG, Magdy Abdelwahab Abdelrahman N, Mallick D, Margetis S, Markert C, Matis HS, Mazer JA, Minaev NG, Mioduszewski S, Mohanty B, Mondal MM, Mooney I, Morozov DA, Mukherjee A, Nagy M, Nam JD, Nasim M, Nayak K, Neff D, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nishitani R, Nogach LV, Nonaka T, Nunes AS, Odyniec G, Ogawa A, Oh S, Okorokov VA, Page BS, Pak R, Pan J, Pandav A, Pandey AK, Panebratsev Y, Parfenov P, Pawlik B, Pawlowska D, Perkins C, Pinsky L, Pintér RL, Pluta J, Pokhrel BR, Ponimatkin G, Porter J, Posik M, Prozorova V, Pruthi NK, Przybycien M, Putschke J, Qiu H, Quintero A, Racz C, Radhakrishnan SK, Raha N, Ray RL, Reed R, Ritter HG, Robotkova M, Rogachevskiy OV, Romero JL, Roy D, Ruan L, Rusnak J, Sahoo AK, Sahoo NR, Sako H, Salur S, Sandweiss J, Sato S, Schmidke WB, Schmitz N, Schweid BR, Seck F, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Shao T, Sheikh AI, Shen DY, Shi SS, Shi Y, Shou QY, Sichtermann EP, Sikora R, Simko M, Singh J, Singha S, Skoby MJ, Smirnov N, Söhngen Y, Solyst W, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stefaniak M, Stewart DJ, Strikhanov M, Stringfellow B, Suaide AAP, Sumbera M, Summa B, Sun XM, Sun X, Sun Y, Sun Y, Surrow B, Svirida DN, Sweger ZW, Szymanski P, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Todoroki T, Tokarev M, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Truhlar T, Trzeciak BA, Tsai OD, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vasiliev AN, Vassiliev I, Verkest V, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang JS, Wang P, Wang X, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Wen L, Westfall GD, Wieman H, Wissink SW, Wu J, Wu J, Wu Y, Xi B, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu Y, Xu Z, Xu Z, Yan G, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yu Y, Zbroszczyk H, Zha W, Zhang C, Zhang D, Zhang J, Zhang S, Zhang S, Zhang XP, Zhang Y, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao J, Zhou C, Zhou Y, Zhu X, Zurek M, Zyzak M. Evidence for Nonlinear Gluon Effects in QCD and Their Mass Number Dependence at STAR. PHYSICAL REVIEW LETTERS 2022; 129:092501. [PMID: 36083674 DOI: 10.1103/physrevlett.129.092501] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 07/12/2022] [Accepted: 07/29/2022] [Indexed: 06/15/2023]
Abstract
The STAR Collaboration reports measurements of back-to-back azimuthal correlations of di-π^{0}s produced at forward pseudorapidities (2.6<η<4.0) in p+p, p+Al, and p+Au collisions at a center-of-mass energy of 200 GeV. We observe a clear suppression of the correlated yields of back-to-back π^{0} pairs in p+Al and p+Au collisions compared to the p+p data. The observed suppression of back-to-back pairs as a function of transverse momentum suggests nonlinear gluon dynamics arising at high parton densities. The larger suppression found in p+Au relative to p+Al collisions exhibits a dependence of the saturation scale Q_{s}^{2} on the mass number A. A linear scaling of the suppression with A^{1/3} is observed with a slope of -0.09±0.01.
Collapse
|
169
|
Hua HJ, Wu J, Li KD, Song GX, Li H. [Analysis of clinicopathological characteristics of gastric-type inverted hyperplastic polyps]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2022; 51:749-751. [PMID: 35922166 DOI: 10.3760/cma.j.cn112151-20220117-00039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
|
170
|
Aad G, Abbott B, Abbott DC, Abed Abud A, Abeling K, Abhayasinghe DK, Abidi SH, Aboulhorma A, Abramowicz H, Abreu H, Abulaiti Y, Abusleme Hoffman AC, Acharya BS, Achkar B, Adam L, Adam Bourdarios C, Adamczyk L, Adamek L, Addepalli SV, Adelman J, Adiguzel A, Adorni S, Adye T, Affolder AA, Afik Y, Agapopoulou C, Agaras MN, Agarwala J, Aggarwal A, Agheorghiesei C, Aguilar-Saavedra JA, Ahmad A, Ahmadov F, Ahmed WS, Ai X, Aielli G, Aizenberg I, Akbiyik M, Åkesson TPA, Akimov AV, Al Khoury K, Alberghi GL, Albert J, Albicocco P, Alconada Verzini MJ, Alderweireldt S, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi A, Alfonsi F, Alhroob M, Ali B, Ali S, Aliev M, Alimonti G, Allaire C, Allbrooke BMM, Allport PP, Aloisio A, Alonso F, Alpigiani C, Alunno Camelia E, Alvarez Estevez M, Alviggi MG, Amaral Coutinho Y, Ambler A, Ambroz L, Amelung C, Amidei D, Amor Dos Santos SP, Amoroso S, Amos KR, Amrouche CS, Ananiev V, Anastopoulos C, Andari N, Andeen T, Anders JK, Andrean SY, Andreazza A, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Antrim DJA, Anulli F, Aoki M, Aparisi Pozo JA, Aparo MA, Aperio Bella L, Aranzabal N, Araujo Ferraz V, Arcangeletti C, Arce ATH, Arena E, Arguin JF, Argyropoulos S, Arling JH, Armbruster AJ, Arnaez O, Arnold H, Arrubarrena Tame ZP, Artoni G, Asada H, Asai K, Asai S, Asbah NA, Asimakopoulou EM, Assahsah J, Assamagan K, Astalos R, Atkin RJ, Atkinson M, Atlay NB, Atmani H, Atmasiddha PA, Augsten K, Auricchio S, Austrup VA, Avner G, Avolio G, Ayoub MK, Azuelos G, Babal D, Bachacou H, Bachas K, Bachiu A, Backman F, Badea A, Bagnaia P, Bahmani M, Bailey AJ, Bailey VR, Baines JT, Bakalis C, Baker OK, Bakker PJ, Bakos E, Bakshi Gupta D, Balaji S, Balasubramanian R, Baldin EM, Balek P, Ballabene E, Balli F, Baltes LM, Balunas WK, Balz J, Banas E, Bandieramonte M, Bandyopadhyay A, Bansal S, Barak L, Barberio EL, Barberis D, Barbero M, Barbour G, Barends KN, Barillari T, Barisits MS, Barkeloo J, Barklow T, Barnett RM, Baron P, Baroncelli A, Barone G, Barr AJ, Barranco Navarro L, Barreiro F, Barreiro Guimarães da Costa J, Barron U, Barsov S, Bartels F, Bartoldus R, Bartolini G, Barton AE, Bartos P, Basalaev A, Basan A, Baselga M, Bashta I, Bassalat A, Basso MJ, Basson CR, Bates RL, Batlamous S, Batley JR, Batool B, Battaglia M, Bauce M, Bauer F, Bauer P, Bayirli A, Beacham JB, Beau T, Beauchemin PH, Becherer F, Bechtle P, Beck HP, Becker K, Becot C, Beddall AJ, Bednyakov VA, Bee CP, Beemster LJ, Beermann TA, Begalli M, Begel M, Behera A, Behr JK, Beirao Da Cruz E Silva C, Beirer JF, Beisiegel F, Belfkir M, Bella G, Bellagamba L, Bellerive A, Bellos P, Beloborodov K, Belotskiy K, Belyaev NL, Benchekroun D, Benhammou Y, Benjamin DP, Benoit M, Bensinger JR, Bentvelsen S, Beresford L, Beretta M, Berge D, Bergeaas Kuutmann E, Berger N, Bergmann B, Bergsten LJ, Beringer J, Berlendis S, Bernardi G, Bernius C, Bernlochner FU, Berry T, Berta P, Bertram IA, Bessidskaia Bylund O, Bethke S, Betti A, Bevan AJ, Bhatta S, Bhattacharya DS, Bhattarai P, Bhopatkar VS, Bi R, Bi R, Bianchi RM, Biebel O, Bielski R, Biesuz NV, Biglietti M, Billoud TRV, Bindi M, Bingul A, Bini C, Biondi S, Biondini A, Birch-Sykes CJ, Bird GA, Birman M, Bisanz T, Biswal JP, Biswas D, Bitadze A, Bjørke K, Bloch I, Blocker C, Blue A, Blumenschein U, Blumenthal J, Bobbink GJ, Bobrovnikov VS, Boehler M, Bogavac D, Bogdanchikov AG, Bohm C, Boisvert V, Bokan P, Bold T, Bomben M, Bona M, Boonekamp M, Booth CD, Borbély AG, Borecka-Bielska HM, Borgna LS, Borissov G, Bortoletto D, Boscherini D, Bosman M, Bossio Sola JD, Bouaouda K, Boudreau J, Bouhova-Thacker EV, Boumediene D, Bouquet R, Boveia A, Boyd J, Boye D, Boyko IR, Bracinik J, Brahimi N, Brandt G, Brandt O, Braren F, Brau B, Brau JE, Breaden Madden WD, Brendlinger K, Brener R, Brenner L, Brenner R, Bressler S, Brickwedde B, Britton D, Britzger D, Brock I, Brooijmans G, Brooks WK, Brost E, Bruckman de Renstrom PA, Brüers B, Bruncko D, Bruni A, Bruni G, Bruschi M, Bruscino N, Bryngemark L, Buanes T, Buat Q, Buchholz P, Buckley AG, Budagov IA, Bugge MK, Bulekov O, Bullard BA, Burdin S, Burgard CD, Burger AM, Burghgrave B, Burr JTP, Burton CD, Burzynski JC, Busch EL, Büscher V, Bussey PJ, Butler JM, Buttar CM, Butterworth JM, Buttinger W, Buxo Vazquez CJ, Buzykaev AR, Cabras G, Cabrera Urbán S, Caforio D, Cai H, Cairo VMM, Cakir O, Calace N, Calafiura P, Calderini G, Calfayan P, Callea G, Caloba LP, Calvet D, Calvet S, Calvet TP, Calvetti M, Camacho Toro R, Camarda S, Camarero Munoz D, Camarri P, Camerlingo MT, Cameron D, Camincher C, Campanelli M, Camplani A, Canale V, Canesse A, Cano Bret M, Cantero J, Cao Y, Capocasa F, Capua M, Carbone A, Cardarelli R, Cardenas JCJ, Cardillo F, Carducci G, Carli T, Carlino G, Carlson BT, Carlson EM, Carminati L, Carnesale M, Caron S, Carquin E, Carrá S, Carratta G, Carter JWS, Carter TM, Casadei D, Casado MP, Casha AF, Castiglia EG, Castillo FL, Castillo Garcia L, Castillo Gimenez V, Castro NF, Catinaccio A, Catmore JR, Cavaliere V, Cavalli N, Cavasinni V, Celebi E, Celli F, Centonze MS, Cerny K, Cerqueira AS, Cerri A, Cerrito L, Cerutti F, Cervelli A, Cetin SA, Chadi Z, Chakraborty D, Chala M, Chan J, Chan WS, Chan WY, Chapman JD, Chargeishvili B, Charlton DG, Charman TP, Chatterjee M, Chekanov S, Chekulaev SV, Chelkov GA, Chen A, Chen B, Chen B, Chen C, Chen H, Chen H, Chen J, Chen J, Chen S, Chen SJ, Chen X, Chen X, Chen Y, Cheng CL, Cheng HC, Cheplakov A, Cheremushkina E, Cherepanova E, Cherkaoui El Moursli R, Cheu E, Cheung K, Chevalier L, Chiarella V, Chiarelli G, Chiodini G, Chisholm AS, Chitan A, Chiu YH, Chizhov MV, Choi K, Chomont AR, Chou Y, Chow EYS, Chowdhury T, Christopher LD, Chu MC, Chu X, Chudoba J, Chwastowski JJ, Cieri D, Ciesla KM, Cindro V, Ciocio A, Cirotto F, Citron ZH, Citterio M, Ciubotaru DA, Ciungu BM, Clark A, Clark PJ, Clavijo Columbie JM, Clawson SE, Clement C, Clissa L, Coadou Y, Cobal M, Coccaro A, Barrue RFC, Coelho Lopes De Sa R, Coelli S, Cohen H, Coimbra AEC, Cole B, Collot J, Conde Muiño P, Connell SH, Connelly IA, Conroy EI, Conventi F, Cooke HG, Cooper-Sarkar AM, Cormier F, Corpe LD, Corradi M, Corrigan EE, Corriveau F, Costa MJ, Costanza F, Costanzo D, Cote BM, Cowan G, Cowley JW, Cranmer K, Crépé-Renaudin S, Crescioli F, Cristinziani M, Cristoforetti M, Croft V, Crosetti G, Cueto A, Cuhadar Donszelmann T, Cui H, Cui Z, Cukierman AR, Cunningham WR, Curcio F, Czodrowski P, Czurylo MM, De Sousa MJDCS, Da Fonseca Pinto JV, Da Via C, Dabrowski W, Dado T, Dahbi S, Dai T, Dallapiccola C, Dam M, D'amen G, D'Amico V, Damp J, Dandoy JR, Daneri MF, Danninger M, Dao V, Darbo G, Darmora S, Dattagupta A, D'Auria S, David C, Davidek T, Davis DR, Davis-Purcell B, Dawson I, De K, De Asmundis R, De Beurs M, De Castro S, De Groot N, de Jong P, De la Torre H, De Maria A, De Salvo A, De Sanctis U, De Santis M, De Santo A, De Vivie De Regie JB, Dedovich DV, Degens J, Deiana AM, Del Peso J, Del Rio F, Deliot F, Delitzsch CM, Della Pietra M, Della Volpe D, Dell'Acqua A, Dell'Asta L, Delmastro M, Delsart PA, Demers S, Demichev M, Denisov SP, D'Eramo L, Derendarz D, Derue F, Dervan P, Desch K, Dette K, Deutsch C, Deviveiros PO, Di Bello FA, Di Ciaccio A, Di Ciaccio L, Di Domenico A, Di Donato C, Di Girolamo A, Di Gregorio G, Di Luca A, Di Micco B, Di Nardo R, Diaconu C, Dias FA, Vale TDD, Diaz MA, Diaz Capriles FG, Didenko M, Diehl EB, Díez Cornell S, Diez Pardos C, Dimitriadi C, Dimitrievska A, Ding W, Dingfelder J, Dinu IM, Dittmeier SJ, Dittus F, Djama F, Djobava T, Djuvsland JI, Dodsworth D, Doglioni C, Dolejsi J, Dolezal Z, Donadelli M, Dong B, Donini J, D'onofrio A, D'Onofrio M, Dopke J, Doria A, Dova MT, Doyle AT, Drechsler E, Dreyer E, Drobac AS, Du D, du Pree TA, Dubinin F, Dubovsky M, Duchovni E, Duckeck G, Ducu OA, Duda D, Dudarev A, D'uffizi M, Duflot L, Dührssen M, Dülsen C, Dumitriu AE, Dunford M, Dungs S, Dunne K, Duperrin A, Yildiz HD, Düren M, Durglishvili A, Dutta B, Dwyer BL, Dyckes GI, Dyndal M, Dysch S, Dziedzic BS, Eckerova B, Eggleston MG, Egidio Purcino De Souza E, Ehrke LF, Eigen G, Einsweiler K, Ekelof T, El Ghazali Y, El Jarrari H, El Moussaouy A, Ellajosyula V, Ellert M, Ellinghaus F, Elliot AA, Ellis N, Elmsheuser J, Elsing M, Emeliyanov D, Emerman A, Enari Y, Ene I, Erdmann J, Ereditato A, Erland PA, Errenst M, Escalier M, Escobar C, Etzion E, Evans G, Evans H, Evans MO, Ezhilov A, Ezzarqtouni S, Fabbri F, Fabbri L, Facini G, Fadeyev V, Fakhrutdinov RM, Falciano S, Falke PJ, Falke S, Faltova J, Fan Y, Fang Y, Fanourakis G, Fanti M, Faraj M, Farbin A, Farilla A, Farina EM, Farooque T, Farrington SM, Fassi F, Fassouliotis D, Faucci Giannelli M, Fawcett WJ, Fayard L, Fedin OL, Fedotov G, Feickert M, Feligioni L, Fell A, Fellers DE, Feng C, Feng M, Fenton MJ, Fenyuk AB, Ferguson SW, Fernandez Pretel JA, Ferrando J, Ferrari A, Ferrari P, Ferrari R, Ferrere D, Ferretti C, Fiedler F, Filipčič A, Filthaut F, Fiolhais MCN, Fiorini L, Fischer F, Fisher WC, Fitschen T, Fleck I, Fleischmann P, Flick T, Flores L, Flores M, Flores Castillo LR, Follega FM, Fomin N, Foo JH, Forland BC, Formica A, Forti AC, Fortin E, Fortman AW, Foti MG, Fountas L, Fournier D, Fox H, Francavilla P, Francescato S, Franchini M, Franchino S, Francis D, Franco L, Franconi L, Franklin M, Frattari G, Freegard AC, Freeman PM, Freund WS, Freundlich EM, Froidevaux D, Frost JA, Fu Y, Fujimoto M, Fullana Torregrosa E, Fuster J, Gabrielli A, Gabrielli A, Gadow P, Gagliardi G, Gagnon LG, Gallardo GE, Gallas EJ, Gallop BJ, Gamboa Goni R, Gan KK, Ganguly S, Gao J, Gao Y, Garay Walls FM, Garcia B, García C, García Navarro JE, García Pascual JA, Garcia-Sciveres M, Gardner RW, Garg D, Garg RB, Gargiulo S, Garner CA, Garonne V, Gasiorowski SJ, Gaspar P, Gaudio G, Gauzzi P, Gavrilenko IL, Gavrilyuk A, Gay C, Gaycken G, Gazis EN, Geanta AA, Gee CM, Geisen J, Geisen M, Gemme C, Genest MH, Gentile S, George S, George WF, Geralis T, Gerlach LO, Gessinger-Befurt P, Ghasemi Bostanabad M, Ghosh A, Ghosh A, Giacobbe B, Giagu S, Giangiacomi N, Giannetti P, Giannini A, Gibson SM, Gignac M, Gil DT, Gilbert BJ, Gillberg D, Gilles G, Gillwald NEK, Ginabat L, Gingrich DM, Giordani MP, Giraud PF, Giugliarelli G, Giugni D, Giuli F, Gkialas I, Gkountoumis P, Gladilin LK, Glasman C, Gledhill GR, Glisic M, Gnesi I, Go Y, Goblirsch-Kolb M, Godin D, Goldfarb S, Golling T, Golubkov D, Gombas JP, Gomes A, Goncalves Gama R, Gonçalo R, Gonella G, Gonella L, Gongadze A, Gonnella F, Gonski JL, González de la Hoz S, Gonzalez Fernandez S, Gonzalez Lopez R, Gonzalez Renteria C, Gonzalez Suarez R, Gonzalez-Sevilla S, Gonzalvo Rodriguez GR, González Andana RY, Goossens L, Gorasia NA, Gorbounov PA, Gordon HA, Gorini B, Gorini E, Gorišek A, Goshaw AT, Gostkin MI, Gottardo CA, Gouighri M, Goumarre V, Goussiou AG, Govender N, Goy C, Grabowska-Bold I, Graham K, Gramstad E, Grancagnolo S, Grandi M, Gratchev V, Gravila PM, Gravili FG, Gray HM, Grefe C, Gregor IM, Grenier P, Grevtsov K, Grieco C, Grillo AA, Grimm K, Grinstein S, Grivaz JF, Groh S, Gross E, Grosse-Knetter J, Grud C, Grummer A, Grundy JC, Guan L, Guan W, Gubbels C, Guerrero Rojas JGR, Guescini F, Guest D, Gugel R, Guida A, Guillemin T, Guindon S, Guo F, Guo J, Guo L, Guo Y, Gupta R, Gurbuz S, Gustavino G, Guth M, Gutierrez P, Gutierrez Zagazeta LF, Gutschow C, Guyot C, Gwenlan C, Gwilliam CB, Haaland ES, Haas A, Habedank M, Haber C, Hadavand HK, Hadef A, Hadzic S, Haleem M, Haley J, Hall JJ, Hallewell GD, Halser L, Hamano K, Hamdaoui H, Hamer M, Hamity GN, Han J, Han K, Han L, Han L, Han S, Han YF, Hanagaki K, Hance M, Hangal DA, Hank MD, Hankache R, Hansen E, Hansen JB, Hansen JD, Hansen PH, Hara K, Harada D, Harenberg T, Harkusha S, Harris YT, Harrison PF, Hartman NM, Hartmann NM, Hasegawa Y, Hasib A, Haug S, Hauser R, Havranek M, Hawkes CM, Hawkings RJ, Hayashida S, Hayden D, Hayes C, Hayes RL, Hays CP, Hays JM, Hayward HS, He F, He Y, He Y, Heath MP, Hedberg V, Heggelund AL, Hehir ND, Heidegger C, Heidegger KK, Heidorn WD, Heilman J, Heim S, Heim T, Heinemann B, Heinlein JG, Heinrich JJ, Heinrich L, Hejbal J, Helary L, Held A, Helling CM, Hellman S, Helsens C, Henderson RCW, Henkelmann L, Henriques Correia AM, Herde H, Hernández Jiménez Y, Herr H, Herrmann MG, Herrmann T, Herten G, Hertenberger R, Hervas L, Hessey NP, Hibi H, Higón-Rodriguez E, Hillier SJ, Hinchliffe I, Hinterkeuser F, Hirose M, Hirose S, Hirschbuehl D, Hiti B, Hladik O, Hobbs J, Hobincu R, Hod N, Hodgkinson MC, Hodkinson BH, Hoecker A, Hofer J, Hohn D, Holm T, Holzbock M, Hommels LBAH, Honan BP, Hong J, Hong TM, Hong Y, Honig JC, Hönle A, Hooberman BH, Hopkins WH, Horii Y, Horyn LA, Hou S, Howarth J, Hoya J, Hrabovsky M, Hrynevich A, Hryn'ova T, Hsu PJ, Hsu SC, Hu Q, Hu S, Hu YF, Huang DP, Huang X, Huang Y, Huang Y, Hubacek Z, Huebner M, Huegging F, Huffman TB, Huhtinen M, Huiberts SK, Hulsken R, Huseynov N, Huston J, Huth J, Hyneman R, Hyrych S, Iacobucci G, Iakovidis G, Ibragimov I, Iconomidou-Fayard L, Iengo P, Iguchi R, Iizawa T, Ikegami Y, Ilg A, Ilic N, Imam H, Ingebretsen Carlson T, Introzzi G, Iodice M, Ippolito V, Ishino M, Islam W, Issever C, Istin S, Ito H, Iturbe Ponce JM, Iuppa R, Ivina A, Izen JM, Izzo V, Jacka P, Jackson P, Jacobs RM, Jaeger BP, Jagfeld CS, Jäkel G, Jakobs K, Jakoubek T, Jamieson J, Janas KW, Jarlskog G, Jaspan AE, Javůrek T, Javurkova M, Jeanneau F, Jeanty L, Jejelava J, Jenni P, Jézéquel S, Jia J, Jia Z, Jiang Y, Jiggins S, Jimenez Pena J, Jin S, Jinaru A, Jinnouchi O, Jivan H, Johansson P, Johns KA, Johnson CA, Jones DM, Jones E, Jones RWL, Jones TJ, Jovicevic J, Ju X, Junggeburth JJ, Juste Rozas A, Kabana S, Kaczmarska A, Kado M, Kagan H, Kagan M, Kahn A, Kahn A, Kahra C, Kaji T, Kajomovitz E, Kakati N, Kalderon CW, Kamenshchikov A, Kang NJ, Kano Y, Kar D, Karava K, Kareem MJ, Karentzos E, Karkanias I, Karpov SN, Karpova ZM, Kartvelishvili V, Karyukhin AN, Kasimi E, Kato C, Katzy J, Kaur S, Kawade K, Kawagoe K, Kawaguchi T, Kawamoto T, Kawamura G, Kay EF, Kaya FI, Kazakos S, Kazanin VF, Ke Y, Keaveney JM, Keeler R, Keller JS, Kelly AS, Kelsey D, Kempster JJ, Kendrick J, Kennedy KE, Kepka O, Kersten S, Kerševan BP, Ketabchi Haghighat S, Khandoga M, Khanov A, Kharlamov AG, Kharlamova T, Khoda EE, Khoo TJ, Khoriauli G, Khramov E, Khubua J, Kiehn M, Kilgallon A, Kim E, Kim YK, Kimura N, Kirchhoff A, Kirchmeier D, Kirfel C, Kirk J, Kiryunin AE, Kishimoto T, Kisliuk DP, Kitsaki C, Kivernyk O, Klassen M, Klein C, Klein L, Klein MH, Klein M, Klein U, Klimek P, Klimentov A, Klimpel F, Klingl T, Klioutchnikova T, Klitzner FF, Kluit P, Kluth S, Kneringer E, Knight TM, Knue A, Kobayashi D, Kobayashi R, Kocian M, Kodama T, Kodys P, Koeck DM, Koenig PT, Koffas T, Köhler NM, Kolb M, Koletsou I, Komarek T, Köneke K, Kong AXY, Kono T, Konstantinides V, Konstantinidis N, Konya B, Kopeliansky R, Koperny S, Korcyl K, Kordas K, Koren G, Korn A, Korn S, Korolkov I, Korotkova N, Kortman B, Kortner O, Kortner S, Kostecka WH, Kostyukhin VV, Kotsokechagia A, Kotwal A, Koulouris A, Kourkoumeli-Charalampidi A, Kourkoumelis C, Kourlitis E, Kovanda O, Kowalewski R, Kozanecki W, Kozhin AS, Kramarenko VA, Kramberger G, Kramer P, Krasny MW, Krasznahorkay A, Kremer JA, Kretzschmar J, Kreul K, Krieger P, Krieter F, Krishnamurthy S, Krishnan A, Krivos M, Krizka K, Kroeninger K, Kroha H, Kroll J, Kroll J, Krowpman KS, Kruchonak U, Krüger H, Krumnack N, Kruse MC, Krzysiak JA, Kubota A, Kuchinskaia O, Kuday S, Kuechler D, Kuechler JT, Kuehn S, Kuhl T, Kukhtin V, Kulchitsky Y, Kuleshov S, Kumar M, Kumari N, Kuna M, Kupco A, Kupfer T, Kuprash O, Kurashige H, Kurchaninov LL, Kurochkin YA, Kurova A, Kuwertz ES, Kuze M, Kvam AK, Kvita J, Kwan T, Kwok KW, Lacasta C, Lacava F, Lacker H, Lacour D, Lad NN, Ladygin E, Laforge B, Lagouri T, Lai S, Lakomiec IK, Lalloue N, Lambert JE, Lammers S, Lampl W, Lampoudis C, Lançon E, Landgraf U, Landon MPJ, Lang VS, Lange JC, Langenberg RJ, Lankford AJ, Lanni F, Lantzsch K, Lanza A, Lapertosa A, Laporte JF, Lari T, Lasagni Manghi F, Lassnig M, Latonova V, Lau TS, Laudrain A, Laurier A, Lavorgna M, Lawlor SD, Lawrence Z, Lazzaroni M, Le B, Leban B, Lebedev A, LeBlanc M, LeCompte T, Ledroit-Guillon F, Lee ACA, Lee GR, Lee L, Lee SC, Leeuw LL, Lefebvre B, Lefebvre HP, Lefebvre M, Leggett C, Lehmann K, Lehmann Miotto G, Leight WA, Leisos A, Leite MAL, Leitgeb CE, Leitner R, Leney KJC, Lenz T, Leone S, Leonidopoulos C, Leopold A, Leroy C, Les R, Lester CG, Levchenko M, Levêque J, Levin D, Levinson LJ, Lewis DJ, Li B, Li B, Li C, Li CQ, Li H, Li H, Li H, Li J, Li K, Li L, Li M, Li QY, Li S, Li T, Li X, Li Z, Li Z, Li Z, Li Z, Liang Z, Liberatore M, Liberti B, Lie K, Lieber Marin J, Lin K, Linck RA, Lindley RE, Lindon JH, Linss A, Lipeles E, Lipniacka A, Liss TM, Lister A, Little JD, Liu B, Liu BX, Liu D, Liu JB, Liu JKK, Liu K, Liu M, Liu MY, Liu P, Liu Q, Liu X, Liu Y, Liu Y, Liu YL, Liu YW, Livan M, Llorente Merino J, Lloyd SL, Lobodzinska EM, Loch P, Loffredo S, Lohse T, Lohwasser K, Lokajicek M, Long JD, Longarini I, Longo L, Longo R, Lopez Paz I, Lopez Solis A, Lorenz J, Lorenzo Martinez N, Lory AM, Lösle A, Lou X, Lou X, Lounis A, Love J, Love PA, Lozano Bahilo JJ, Lu G, Lu M, Lu S, Lu YJ, Lubatti HJ, Luci C, Lucio Alves FL, Lucotte A, Luehring F, Luise I, Lundberg O, Lund-Jensen B, Luongo NA, Lutz MS, Lynn D, Lyons H, Lysak R, Lytken E, Lyu F, Lyubushkin V, Lyubushkina T, Ma H, Ma LL, Ma Y, Mac Donell DM, Maccarrone G, MacDonald JC, Madar R, Mader WF, Maeda J, Maeno T, Maerker M, Magerl V, Magro J, Mahon DJ, Maidantchik C, Maio A, Maj K, Majersky O, Majewski S, Makovec N, Maksimovic V, Malaescu B, Malecki P, Maleev VP, Malek F, Malito D, Mallik U, Malone C, Maltezos S, Malyukov S, Mamuzic J, Mancini G, Mandalia JP, Mandić I, Manhaes de Andrade Filho L, Maniatis IM, Manisha M, Manjarres Ramos J, Mankad DC, Mankinen KH, Mann A, Manousos A, Mansoulie B, Manzoni S, Marantis A, Marchiori G, Marcisovsky M, Marcoccia L, Marcon C, Marinescu M, Marjanovic M, Marshall Z, Marti-Garcia S, Martin TA, Martin VJ, Martin Dit Latour B, Martinelli L, Martinez M, Martinez Agullo P, Martinez Outschoorn VI, Martinez Suarez P, Martin-Haugh S, Martoiu VS, Martyniuk AC, Marzin A, Maschek SR, Masetti L, Mashimo T, Masik J, Maslennikov AL, Massa L, Massarotti P, Mastrandrea P, Mastroberardino A, Masubuchi T, Mathisen T, Matic A, Matsuzawa N, Maurer J, Maček B, Maximov DA, Mazini R, Maznas I, Mazza M, Mazza SM, Mc Ginn C, Mc Gowan JP, Mc Kee SP, McCarthy TG, McCormack WP, McDonald EF, McDougall AE, Mcfayden JA, Mchedlidze G, McKay MA, Mckenzie RP, Mclaughlin DJ, McLean KD, McMahon SJ, McNamara PC, McPherson RA, Mdhluli JE, Meehan S, Megy T, Mehlhase S, Mehta A, Meirose B, Melini D, Mellado Garcia BR, Melo AH, Meloni F, Melzer A, Gouveia EDM, Mendes Jacques Da Costa AM, Meng HY, Meng L, Menke S, Mentink M, Meoni E, Merlassino C, Merola L, Meroni C, Merz G, Meshkov O, Meshreki JKR, Metcalfe J, Mete AS, Meyer C, Meyer JP, Michetti M, Middleton RP, Mijović L, Mikenberg G, Mikestikova M, Mikuž M, Mildner H, Milic A, Milke CD, Miller DW, Miller LS, Milov A, Milstead DA, Min T, Minaenko AA, Minashvili IA, Mince L, Mincer AI, Mindur B, Mineev M, Minegishi Y, Mino Y, Mir LM, Miralles Lopez M, Mironova M, Mitani T, Mitra A, Mitsou VA, Miu O, Miyagawa PS, Miyazaki Y, Mizukami A, Mjörnmark JU, Mkrtchyan T, Mlynarikova M, Moa T, Mobius S, Mochizuki K, Moder P, Mogg P, Mohammed AF, Mohapatra S, Mokgatitswane G, Mondal B, Mondal S, Mönig K, Monnier E, Monsonis Romero L, Montejo Berlingen J, Montella M, Monticelli F, Morange N, De Carvalho ALM, Moreno Llácer M, Moreno Martinez C, Morettini P, Morgenstern S, Mori D, Morii M, Morinaga M, Morisbak V, Morley AK, Morris AP, Morvaj L, Moschovakos P, Moser B, Mosidze M, Moskalets T, Moskvitina P, Moss J, Moyse EJW, Muanza S, Mueller J, Mueller R, Muenstermann D, Mullier GA, Mullin JJ, Mungo DP, Munoz Martinez JL, Munoz Sanchez FJ, Murin M, Murray WJ, Murrone A, Muse JM, Muškinja M, Mwewa C, Myagkov AG, Myers AJ, Myers AA, Myers G, Myska M, Nachman BP, Nackenhorst O, Nag AN, Nagai K, Nagano K, Nagle JL, Nagy E, Nairz AM, Nakahama Y, Nakamura K, Nanjo H, Napolitano F, Narayan R, Narayanan EA, Naryshkin I, Naseri M, Nass C, Navarro G, Navarro-Gonzalez J, Nayak R, Nechaeva PY, Nechansky F, Neep TJ, Negri A, Negrini M, Nellist C, Nelson C, Nelson K, Nemecek S, Nessi M, Neubauer MS, Neuhaus F, Neundorf J, Newhouse R, Newman PR, Ng CW, Ng YS, Ng YWY, Ngair B, Nguyen HDN, Nickerson RB, Nicolaidou R, Nielsen DS, Nielsen J, Niemeyer M, Nikiforou N, Nikolaenko V, Nikolic-Audit I, Nikolopoulos K, Nilsson P, Nindhito HR, Nisati A, Nishu N, Nisius R, Noacco Rosende SJ, Nobe T, Noel DL, Noguchi Y, Nomidis I, Nomura MA, Norfolk MB, Norisam RRB, Novak J, Novak T, Novgorodova O, Novotny L, Novotny R, Nozka L, Ntekas K, Nurse E, Oakham FG, Ocariz J, Ochi A, Ochoa I, Ochoa-Ricoux JP, Oda S, Odaka S, Oerdek S, Ogrodnik A, Oh A, Ohm CC, Oide H, Oishi R, Ojeda ML, Okazaki Y, O'Keefe MW, Okumura Y, Olariu A, Seabra LFO, Olivares Pino SA, Oliveira Damazio D, Oliveira Goncalves D, Oliver JL, Olsson MJR, Olszewski A, Olszowska J, Öncel ÖO, O'Neil DC, O'neill AP, Onofre A, Onyisi PUE, Oreamuno Madriz RG, Oreglia MJ, Orellana GE, Orestano D, Orlando N, Orr RS, O'Shea V, Ospanov R, Otero Y Garzon G, Otono H, Ott PS, Ottino GJ, Ouchrif M, Ouellette J, Ould-Saada F, Owen M, Owen RE, Oyulmaz KY, Ozcan VE, Ozturk N, Ozturk S, Pacalt J, Pacey HA, Pachal K, Pacheco Pages A, Padilla Aranda C, Pagan Griso S, Palacino G, Palazzo S, Palestini S, Palka M, Pan J, Panchal DK, Pandini CE, Panduro Vazquez JG, Pani P, Panizzo G, Paolozzi L, Papadatos C, Parajuli S, Paramonov A, Paraskevopoulos C, Paredes Hernandez D, Parida B, Park TH, Parker AJ, Parker MA, Parodi F, Parrish EW, Parrish VA, Parsons JA, Parzefall U, Pascual Dias B, Pascual Dominguez L, Pascuzzi VR, Pasquali F, Pasqualucci E, Passaggio S, Pastore F, Pasuwan P, Pater JR, Pathak A, Patton J, Pauly T, Pearkes J, Pedersen M, Pedro R, Peleganchuk SV, Penc O, Peng C, Peng H, Penzin M, Peralva BS, Peixoto APP, Pereira Sanchez L, Perepelitsa DV, Perez Codina E, Perganti M, Perini L, Pernegger H, Perrella S, Perrevoort A, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petousis V, Petridou C, Petrukhin A, Pettee M, Pettersson NE, Petukhova K, Peyaud A, Pezoa R, Pezzotti L, Pezzullo G, Pham T, Phillips PW, Phipps MW, Piacquadio G, Pianori E, Piazza F, Piegaia R, Pietreanu D, Pilkington AD, Pinamonti M, Pinfold JL, Pitman Donaldson C, Pizzi DA, Pizzimento L, Pizzini A, Pleier MA, Plesanovs V, Pleskot V, Plotnikova E, Poddar G, Poettgen R, Poggi R, Poggioli L, Pogrebnyak I, Pohl D, Pokharel I, Polacek S, Polesello G, Poley A, Polifka R, Polini A, Pollard CS, Pollock ZB, Polychronakos V, Ponomarenko D, Pontecorvo L, Popa S, Popeneciu GA, Portales L, Portillo Quintero DM, Pospisil S, Postolache P, Potamianos K, Potrap IN, Potter CJ, Potti H, Poulsen T, Poveda J, Pownall G, Pozo Astigarraga ME, Prades Ibanez A, Pralavorio P, Prapa MM, Price D, Primavera M, Principe Martin MA, Proffitt ML, Proklova N, Prokofiev K, Prokoshin F, Proto G, Protopopescu S, Proudfoot J, Przybycien M, Pudzha D, Puzo P, Pyatiizbyantseva D, Qian J, Qin Y, Qiu T, Quadt A, Queitsch-Maitland M, Rabanal Bolanos G, Rafanoharana D, Ragusa F, Raine JA, Rajagopalan S, Ran K, Raskina V, Rassloff DF, Rave S, Ravina B, Ravinovich I, Raymond M, Read AL, Readioff NP, Rebuzzi DM, Redlinger G, Reeves K, Reikher D, Reiss A, Rej A, Rembser C, Renardi A, Renda M, Rendel MB, Rennie AG, Resconi S, Ressegotti M, Resseguie ED, Rettie S, Reynolds B, Reynolds E, Rezaei Estabragh M, Rezanova OL, Reznicek P, Ricci E, Richter R, Richter S, Richter-Was E, Ridel M, Rieck P, Riedler P, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Rinn TT, Rinnagel MP, Ripellino G, Riu I, Rivadeneira P, Rivera Vergara JC, Rizatdinova F, Rizvi E, Rizzi C, Roberts BA, Roberts BR, Robertson SH, Robin M, Robinson D, Robles Gajardo CM, Robles Manzano M, Robson A, Rocchi A, Roda C, Rodriguez Bosca S, Rodriguez Garcia Y, Rodriguez Rodriguez A, Rodríguez Vera AM, Roe S, Roemer JT, Roepe AR, Roggel J, Røhne O, Rojas RA, Roland B, Roland CPA, Roloff J, Romaniouk A, Romano M, Romero Hernandez AC, Rompotis N, Ronzani M, Roos L, Rosati S, Rosser BJ, Rossi E, Rossi E, Rossi E, Rossi LP, Rossini L, Rosten R, Rotaru M, Rottler B, Rousseau D, Rousso D, Rovelli G, Roy A, Rozanov A, Rozen Y, Ruan X, Ruby AJ, Ruggeri TA, Rühr F, Ruiz-Martinez A, Rummler A, Rurikova Z, Rusakovich NA, Russell HL, Rustige L, Rutherfoord JP, Rüttinger EM, Rybacki K, Rybar M, Rye EB, Ryzhov A, Sabater Iglesias JA, Sabatini P, Sabetta L, Sadrozinski HFW, Sadykov R, Safai Tehrani F, Safarzadeh Samani B, Safdari M, Saha S, Sahinsoy M, Sahu A, Saimpert M, Saito M, Saito T, Salamani D, Salamanna G, Salnikov A, Salt J, Salvador Salas A, Salvatore D, Salvatore F, Salzburger A, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Sanchez Pineda A, Sanchez Sebastian V, Sandaker H, Sander CO, Sanderswood IG, Sandesara JA, Sandhoff M, Sandoval C, Sankey DPC, Sansoni A, Santoni C, Santos H, Santpur SN, Santra A, Saoucha KA, Sapronov A, Saraiva JG, Sardain J, Sasaki O, Sato K, Sauer C, Sauerburger F, Sauvan E, Savard P, Sawada R, Sawyer C, Sawyer L, Sayago Galvan I, Sbarra C, Sbrizzi A, Scanlon T, Schaarschmidt J, Schacht P, Schaefer D, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Schanet E, Scharf C, Scharmberg N, Schegelsky VA, Scheirich D, Schenck F, Schernau M, Scheulen C, Schiavi C, Schillaci ZM, Schioppa EJ, Schioppa M, Schlag B, Schleicher KE, Schlenker S, Schmieden K, Schmitt C, Schmitt S, Schoeffel L, Schoening A, Scholer PG, Schopf E, Schott M, Schovancova J, Schramm S, Schroeder F, Schultz-Coulon HC, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schwemling P, Schwienhorst R, Sciandra A, Sciolla G, Scuri F, Scutti F, Sebastiani CD, Sedlaczek K, Seema P, Seidel SC, Seiden A, Seidlitz BD, Seiss T, Seitz C, Seixas JM, Sekhniaidze G, Sekula SJ, Selem L, Semprini-Cesari N, Sen S, Serin L, Serkin L, Sessa M, Severini H, Sevova S, Sforza F, Sfyrla A, Shabalina E, Shaheen R, Shahinian JD, Shaikh NW, Shaked Renous D, Shan LY, Shapiro M, Sharma A, Sharma AS, Sharma S, Shatalov PB, Shaw K, Shaw SM, Sherwood P, Shi L, Shimmin CO, Shimogama Y, Shinner JD, Shipsey IPJ, Shirabe S, Shiyakova M, Shlomi J, Shochet MJ, Shojaii J, Shope DR, Shrestha S, Shrif EM, Shroff MJ, Sicho P, Sickles AM, Sideras Haddad E, Sidiropoulou O, Sidoti A, Siegert F, Sijacki D, Sili F, Silva JM, Silva Oliveira MV, Silverstein SB, Simion S, Simoniello R, Simpson ND, Simsek S, Sindhu S, Sinervo P, Sinetckii V, Singh S, Singh S, Sinha S, Sinha S, Sioli M, Siral I, Sivoklokov SY, Sjölin J, Skaf A, Skorda E, Skubic P, Slawinska M, Smakhtin V, Smart BH, Smiesko J, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith EA, Smith HA, Smith R, Smizanska M, Smolek K, Smykiewicz A, Snesarev AA, Snoek HL, Snyder S, Sobie R, Soffer A, Solans Sanchez CA, Soldatov EY, Soldevila U, Solodkov AA, Solomon S, Soloshenko A, Solovieva K, Solovyanov OV, Solovyev V, Sommer P, Son H, Sonay A, Song WY, Sopczak A, Sopio AL, Sopkova F, Sothilingam V, Sottocornola S, Soualah R, Soukharev AM, Soumaimi Z, South D, Spagnolo S, Spalla M, Spangenberg M, Spanò F, Sperlich D, Spigo G, Spina M, Spinali S, Spiteri DP, Spousta M, Staats EJ, Stabile A, Stamen R, Stamenkovic M, Stampekis A, Standke M, Stanecka E, Stanislaus B, Stanitzki MM, Stankaityte M, Stapf B, Starchenko EA, Stark GH, Stark J, Starko DM, Staroba P, Starovoitov P, Stärz S, Staszewski R, Stavropoulos G, Steentoft J, Steinberg P, Steinhebel AL, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson TJ, Stewart GA, Stockton MC, Stoicea G, Stolarski M, Stonjek S, Straessner A, Strandberg J, Strandberg S, Strauss M, Strebler T, Strizenec P, Ströhmer R, Strom DM, Strom LR, Stroynowski R, Strubig A, Stucci SA, Stugu B, Stupak J, Styles NA, Su D, Su S, Su W, Su X, Sugizaki K, Sulin VV, Sullivan MJ, Sultan DMS, Sultanaliyeva L, Sultansoy S, Sumida T, Sun S, Sun S, Gudnadottir OS, Sutton MR, Svatos M, Swiatlowski M, Swirski T, Sykora I, Sykora M, Sykora T, Ta D, Tackmann K, Taffard A, Tafirout R, Taibah RHM, Takashima R, Takeda K, Takeva EP, Takubo Y, Talby M, Talyshev AA, Tam KC, Tamir NM, Tanaka A, Tanaka J, Tanaka R, Tang J, Tao Z, Tapia Araya S, Tapprogge S, Tarek Abouelfadl Mohamed A, Tarem S, Tariq K, Tarna G, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tateno G, Tayalati Y, Taylor GN, Taylor W, Teagle H, Tee AS, Teixeira De Lima R, Teixeira-Dias P, Teoh JJ, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Themistokleous N, Theveneaux-Pelzer T, Thielmann O, Thomas DW, Thomas JP, Thompson EA, Thompson PD, Thomson E, Thorpe EJ, Tian Y, Tikhomirov V, Tikhonov YA, Timoshenko S, Ting EXL, Tipton P, Tisserant S, Tlou SH, Tnourji A, Todome K, Todorova-Nova S, Todt S, Togawa M, Tojo J, Tokár S, Tokushuku K, Tombs R, Tomoto M, Tompkins L, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toscani M, Tosciri C, Tovey DR, Traeet A, Trandafir IS, Treado CJ, Trefzger T, Tricoli A, Trigger IM, Trincaz-Duvoid S, Trischuk DA, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trovato F, Truong L, Trzebinski M, Trzupek A, Tsai F, Tsai M, Tsiamis A, Tsiareshka PV, Tsirigotis A, Tsiskaridze V, Tskhadadze EG, Tsopoulou M, Tsujikawa Y, Tsukerman II, Tsulaia V, Tsuno S, Tsur O, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tuna AN, Turchikhin S, Turk Cakir I, Turra R, Tuts PM, Tzamarias S, Tzanis P, Tzovara E, Uchida K, Ukegawa F, Ulloa Poblete PA, Unal G, Unal M, Undrus A, Unel G, Uno K, Urban J, Urquijo P, Usai G, Ushioda R, Usman M, Uysal Z, Vacek V, Vachon B, Vadla KOH, Vafeiadis T, Valderanis C, Valdes Santurio E, Valente M, Valentinetti S, Valero A, Vallier A, Valls Ferrer JA, Van Daalen TR, Van Gemmeren P, Van Stroud S, Van Vulpen I, Vanadia M, Vandelli W, Vandenbroucke M, Vandewall ER, Vannicola D, Vannoli L, Vari R, Varnes EW, Varni C, Varol T, Varouchas D, Varvell KE, Vasile ME, Vaslin L, Vasquez GA, Vazeille F, Vazquez Furelos D, Vazquez Schroeder T, Veatch J, Vecchio V, Veen MJ, Veliscek I, Veloce LM, Veloso F, Veneziano S, Ventura A, Verbytskyi A, Verducci M, Vergis C, Verissimo De Araujo M, Verkerke W, Vermeulen JC, Vernieri C, Verschuuren PJ, Vessella M, Vesterbacka ML, Vetterli MC, Vgenopoulos A, Viaux Maira N, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Vigani L, Villa M, Villaplana Perez M, Villhauer EM, Vilucchi E, Vincter MG, Virdee GS, Vishwakarma A, Vittori C, Vivarelli I, Vladimirov V, Voevodina E, Vogel M, Vokac P, Von Ahnen J, Von Toerne E, Vormwald B, Vorobel V, Vorobev K, Vos M, Vossebeld JH, Vozak M, Vozdecky L, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vu NK, Vuillermet R, Vujinovic OV, Vukotic I, Wada S, Wagner C, Wagner W, Wahdan S, Wahlberg H, Wakasa R, Wakida M, Walbrecht VM, Walder J, Walker R, Walkowiak W, Wang AM, Wang AZ, Wang C, Wang C, Wang H, Wang J, Wang P, Wang RJ, Wang R, Wang R, Wang SM, Wang S, Wang T, Wang WT, Wang WX, Wang X, Wang X, Wang X, Wang Y, Wang Z, Wang Z, Wang Z, Warburton A, Ward RJ, Warrack N, Watson AT, Watson MF, Watts G, Waugh BM, Webb AF, Weber C, Weber MS, Weber SA, Weber SM, Wei C, Wei Y, Weidberg AR, Weingarten J, Weirich M, Weiser C, Wenaus T, Wendland B, Wengler T, Wenke NS, Wermes N, Wessels M, Whalen K, Wharton AM, White AS, White A, White MJ, Whiteson D, Wickremasinghe L, Wiedenmann W, Wiel C, Wielers M, Wieseotte N, Wiglesworth C, Wiik-Fuchs LAM, Wilbern DJ, Wilkens HG, Williams DM, Williams HH, Williams S, Willocq S, Windischhofer PJ, Winklmeier F, Winter BT, Wittgen M, Wobisch M, Wolf A, Wölker R, Wollrath J, Wolter MW, Wolters H, Wong VWS, Wongel AF, Worm SD, Wosiek BK, Woźniak KW, Wraight K, Wu J, Wu SL, Wu X, Wu Y, Wu Z, Wuerzinger J, Wyatt TR, Wynne BM, Xella S, Xia L, Xia M, Xiang J, Xiao X, Xie M, Xie X, Xiotidis I, Xu D, Xu H, Xu H, Xu L, Xu R, Xu T, Xu W, Xu Y, Xu Z, Xu Z, Yabsley B, Yacoob S, Yamaguchi N, Yamaguchi Y, Yamauchi H, Yamazaki T, Yamazaki Y, Yan J, Yan S, Yan Z, Yang HJ, Yang HT, Yang S, Yang T, Yang X, Yang X, Yang Y, Yang Z, Yao WM, Yap YC, Ye H, Ye J, Ye S, Ye X, Yeletskikh I, Yexley MR, Yin P, Yorita K, Young CJS, Young C, Yuan M, Yuan R, Yue X, Zaazoua M, Zabinski B, Zacharis G, Zaid E, Zaitsev AM, Zakareishvili T, Zakharchuk N, Zambito S, Zanzi D, Zaplatilek O, Zeißner SV, Zeitnitz C, Zeng JC, Zenger DT, Zenin O, Ženiš T, Zenz S, Zerradi S, Zerwas D, Zhang B, Zhang DF, Zhang G, Zhang J, Zhang K, Zhang L, Zhang M, Zhang R, Zhang S, Zhang X, Zhang X, Zhang Z, Zhao H, Zhao P, Zhao T, Zhao Y, Zhao Z, Zhemchugov A, Zheng Z, Zhong D, Zhou B, Zhou C, Zhou H, Zhou N, Zhou Y, Zhu CG, Zhu C, Zhu HL, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zhulanov V, Zieminska D, Zimine NI, Zimmermann S, Zinsser J, Ziolkowski M, Živković L, Zoccoli A, Zoch K, Zorbas TG, Zormpa O, Zou W, Zwalinski L. Observation of WWW Production in pp Collisions at sqrt[s]=13 TeV with the ATLAS Detector. PHYSICAL REVIEW LETTERS 2022; 129:061803. [PMID: 36018638 DOI: 10.1103/physrevlett.129.061803] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Accepted: 06/23/2022] [Indexed: 06/15/2023]
Abstract
This Letter reports the observation of WWW production and a measurement of its cross section using 139 fb^{-1} of proton-proton collision data recorded at a center-of-mass energy of 13 TeV by the ATLAS detector at the Large Hadron Collider. Events with two same-sign leptons (electrons or muons) and at least two jets, as well as events with three charged leptons, are selected. A multivariate technique is then used to discriminate between signal and background events. Events from WWW production are observed with a significance of 8.0 standard deviations, where the expectation is 5.4 standard deviations. The inclusive WWW production cross section is measured to be 820±100 (stat)±80 (syst) fb, approximately 2.6 standard deviations from the predicted cross section of 511±18 fb calculated at next-to-leading-order QCD and leading-order electroweak accuracy.
Collapse
|
171
|
OuYang Z, Wu J, Wan Z. Pathogenesis and classification of Cesarean scar pregnancy: getting closer to the truth. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2022; 60:297-298. [PMID: 35913382 DOI: 10.1002/uog.24960] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 04/29/2022] [Indexed: 05/27/2023]
|
172
|
Chen HS, Yang Y, Ni J, Chen GF, Ji Y, Yi F, Zhang ZB, Wu J, Cai XL, Shao B, Wang JF, Liu YF, Geng DQ, Qu XH, Li XH, Wei Y, Han SG, Zhu RX, Ding JP, Lyu H, Huang YN, Huang YH, Xiao B, Gong T, Yu XF, Cui LY. [Effects of cinepazide maleate injection on blood pressure in patients with acute ischemic stroke and hypertension]. ZHONGHUA NEI KE ZA ZHI 2022; 61:916-920. [PMID: 35922216 DOI: 10.3760/cma.j.cn112138-20210822-00574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To investigate the blood pressure change in patients with acute ischemic stroke (AIS) and hypertension treated with cinepazide maleate injection. Methods: This was a subgroup analysis of post-marketing clinical confirmation study of cinepazide maleate injection for acute ischemic stroke: a randomized, double-blinded, multicenter, placebo-parallel controlled trial, which conducted in China from August 2016 to February 2019. Eligible patients fulfilled the inclusive criteria of acute anterior circulation ischemic stroke with National Institutes of Health Stroke Scale (NIHSS) scores of 7-25. The primary endpoints were mean blood pressure of AIS patients treated with cinepazide maleate or control, which were assessed during the treatment period (14 days), and the proportion of the patients with normal blood pressure was analyzed after the treatment period. Furthermore, a subgroup analysis was performed to investigate a possible effect of the history of hypertension on outcomes. Results: This analysis included 809 patients with hypertension. There was no significant difference in patients blood pressure and the proportion of patients with normal blood pressure (60.5% vs. 59.0%,P>0.05) between cinepazide maleate group and control group. Conclusion: Administration of cinepazide maleate injection does not affect the management of clinical blood pressure in patients with AIS.
Collapse
|
173
|
Merola J, Chiou A, Foley P, Ardeleanu M, Wu J, Ozturk Z. 298 Sleep improvement with dupilumab in adults with moderate-to-severe atopic dermatitis: Results of the DUPISTAD study. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
174
|
Hua HJ, Wu J, Yang QY, Sun HR, Fan QH, Li H. [Intravascular papillary endothelial hyperplasia of the stomach: report of a case]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2022; 51:664-666. [PMID: 35785842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
|
175
|
Guan DX, Wu J, Zhang J, Guo S, Yu FH, Zhou J, Wang GL, Xu XW. [Clinical features and risk factors for early relapse of pediatric ulcerative colitis]. ZHONGHUA ER KE ZA ZHI = CHINESE JOURNAL OF PEDIATRICS 2022; 60:660-665. [PMID: 35768353 DOI: 10.3760/cma.j.cn112140-20220401-00271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To investigate the clinical features of pediatric ulcerative colitis (UC) and analyze the risk factors of disease relapse. Methods: The clinical data of 79 children with UC diagnosed in Beijing Children's Hospital, Capital Medical University from January 2016 to February 2021 were retrospectively analyzed. They were divided into early relapse group and non-early relapse group according to the clinical relapse within 12 months after diagnosis. T-test, rank sum test, χ2 test or Fisher's exact test were used to compare the variables between the 2 groups, including the clinical features, laboratory examination results and treatments. The Logistic regression was used to analyze the risk factors of early relapse. The cumulative relapse rate during follow-up was calculated by Kaplan-Meier method. Results: Among the 79 UC children, 46 were males and 33 were females, and the age of onset was 10.6 (6.4, 12.7) years. The children were mainly characterized by extensive disease (E3) and pancolitis (E4) (51/79, 65%), moderate to severe activity (48/79, 61%) and moderate to severe inflammation of colonic mucosa (71/79, 90%). Thirty-eight (48%) patients had atypical phenotype and 17 (22%) had extraintestinal manifestations. The follow-up period was 43.9 (22.8, 61.3) months, and of the 41 patients rechecked with colonoscopy, 7 (17%) had disease progression. According to Kaplan-Meier analysis, the cumulative relapse rate of the 79 cases at 3 months, 6 months, 1 year and 2 years after diagnosis were 27% (21/79), 47% (37/79), 57% (45/79) and 73% (53/73), respectively. There were 45 children (57%) in early relapse group and 34 (43%) in non-early relapse group. In early relapse group, hemoglobin and mucosal healing rate were both significantly lower (105 (87, 122) vs. 120 (104, 131) g/L, 28% (7/25) vs. 7/9, Z=-2.38, χ²=4.87, both P<0.05). The rate of steroid-dependent, E3 and step-up therapy during the induction period were all significantly higher than those in non-early relapse group (11/19 vs. 1/12, 24% (11/45) vs. 6% (2/34), 29% (13/45) vs. 6% (2/34), χ²=5.67, 4.85, 6.66, all P<0.05). Multivariate Logistic regression analysis showed that extraintestinal manifestations (OR=4.33, 95%CI 1.05-17.83), E3 (OR=8.27, 95%CI 1.47-46.46) and step-up therapy during the induction period (OR=5.58, 95%CI 1.01-30.77) were independent risk factors for early relapse. Conclusions: Pediatric UC is usually extensive and severe, with atypical phenotype, a high rate of relapse and a risk of disease progression. Extraintestinal manifestations, E3 and step-up therapy during the induction period are independent risk factors for early relapse.
Collapse
|
176
|
Cheng XY, Sang T, Wu J. [Cone-beam CT evaluation of the effect of indirect anchorage of mini-screw assisted clear aligner on molar distalization]. ZHONGHUA KOU QIANG YI XUE ZA ZHI = ZHONGHUA KOUQIANG YIXUE ZAZHI = CHINESE JOURNAL OF STOMATOLOGY 2022; 57:724-732. [PMID: 35790512 DOI: 10.3760/cma.j.cn112144-20211207-00540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To evaluate the effect of indirect anchorage with mini-screw assisted clear aligner on molar distalization. Methods: Twenty-six adult patients [12 males and 14 females, aged 19 to 31 years, mean age (26.4±4.2) years], who were treated in the Department of Orthodontics, the Affiliated Stomatological Hospital of Nanchang University between January 2018 and September 2021, were included. All the patients were treated with clear aligner and mini-screw indirect anchorage to distalize maxillary molars. In the stage of molar distalization, the mini-implants were implanted between the buccal roots of the maxillary first molar and the second premolar, and rigidly connected to the maxillary second premolar as anchorage reenforcement. Until the first molar had distally moved to the designated position, the mini-implants were transferred to the buccal area between the first and the second molars and similar device was connected to the first molar. Cone-beam CT (CBCT) images were taken before the treatment (T0), at the maxillary first molar distally moved to the designated position (T1), and at the anterior teeth alignment finished (T2). The CBCT data were imported into Mimics 20.0 software for three-dimensional reconstruction. After correcting the head position, each reference point was determined in the multi-plane reconstruction view. The bilateral porion, the right orbitale, the nasion, and the anterior nasal spine were selected as reference points to construct the three-dimensional space coordinate system. The positions of the first molar, the second premolar, and the incisor were analyzed three-dimensionally. The three-dimensional position changes of maxillary first molars and maxillary second premolars during the stages of T0-T1, T1-T2, T0-T2, and the mesiodistal and vertical position changes of maxillary central incisors were analyzed. The statistical analysis was carried out using a one-way repeated measures ANOVA. Results: There was a significant difference in the sagittal position changes of the root and cusp of the maxillary central incisors among three time points (F=24.84, P<0.001; F=27.66, P=0.001), but no difference was observed between T0 and T1 (P>0.05). There was a significant difference in lingual retraction of the maxillary central incisor root [(2.17±0.42) mm] and cusp [(1.81±0.28) mm] between T1 and T2 (P<0.05). A significant difference was noted in the sagittal position changes of the root and crown of the maxillary second premolars among three time points (F=17.16, P=0.001; F=57.99, P<0.001). However, no statistical difference was detected between T0 and T1 (P>0.05) and the difference in maxillary second premolar distalization [root (1.95±0.42) mm, cusp (2.53±0.33) mm] was observed between T1 and T2 (P<0.05). There was a statistically significant difference in the sagittal position changes of the root and the crown of the maxillary first molar among three time points (F=9.37, P=0.002; F=140.26, P<0.001). The difference in the maxillary first molar distalization [crown (3.51±0.30) mm, root (1.98±0.25) mm] between T0 and T1 was significant (P<0.05). However, no significant difference in the sagittal position of the maxillary first molars was observed between T1 and T2 (P>0.05). There was a statistically significant difference in the vertical position of the center point of the root in maxillary first molar among three time points (F=59.06, P<0.001), while (2.28±0.24) mm of intrusion between T0 and T1 was exhibited (P<0.05). However, no significant difference was found in the vertical position of the maxillary first molars between T1 and T2 (P>0.05). There was no significant difference in other measurements among three time points (P>0.05). Conclusions: The effect of indirect anchorage with mini-screw-assisted clear aligner on molar distalization was positive.
Collapse
|
177
|
Aad G, Abbott B, Abbott DC, Abeling K, Abidi SH, Aboulhorma A, Abramowicz H, Abreu H, Abulaiti Y, Abusleme Hoffman AC, Acharya BS, Achkar B, Adam L, Bourdarios CA, Adamczyk L, Adamek L, Addepalli SV, Adelman J, Adiguzel A, Adorni S, Adye T, Affolder AA, Afik Y, Agaras MN, Agarwala J, Aggarwal A, Agheorghiesei C, Aguilar-Saavedra JA, Ahmad A, Ahmadov F, Ahmed WS, Ahuja S, Ai X, Aielli G, Aizenberg I, Akbiyik M, Åkesson TPA, Akimov AV, Al Khoury K, Alberghi GL, Albert J, Albicocco P, Verzini MJA, Alderweireldt S, Aleksa M, Aleksandrov IN, Alexa C, Alexopoulos T, Alfonsi A, Alfonsi F, Alhroob M, Ali B, Ali S, Aliev M, Alimonti G, Allaire C, Allbrooke BMM, Allport PP, Aloisio A, Alonso F, Alpigiani C, Camelia EA, Alvarez Estevez M, Alviggi MG, Coutinho YA, Ambler A, Amelung C, Ames CG, Amidei D, Dos Santos SPA, Amoroso S, Amos KR, Amrouche CS, Ananiev V, Anastopoulos C, Andari N, Andeen T, Anders JK, Andrean SY, Andreazza A, Angelidakis S, Angerami A, Anisenkov AV, Annovi A, Antel C, Anthony MT, Antipov E, Antonelli M, Antrim DJA, Anulli F, Aoki M, Aparisi Pozo JA, Aparo MA, Bella LA, Appelt C, Aranzabal N, Ferraz VA, Arcangeletti C, Arce ATH, Arena E, Arguin JF, Argyropoulos S, Arling JH, Armbruster AJ, Arnaez O, Arnold H, Tame ZPA, Artoni G, Asada H, Asai K, Asai S, Asbah NA, Asimakopoulou EM, Assahsah J, Assamagan K, Astalos R, Atkin RJ, Atkinson M, Atlay NB, Atmani H, Atmasiddha PA, Augsten K, Auricchio S, Auriol AD, Austrup VA, Avner G, Avolio G, Axiotis K, Ayoub MK, Azuelos G, Babal D, Bachacou H, Bachas K, Bachiu A, Backman F, Badea A, Bagnaia P, Bahmani M, Bailey AJ, Bailey VR, Baines JT, Bakalis C, Baker OK, Bakker PJ, Bakos E, Gupta DB, Balaji S, Balasubramanian R, Baldin EM, Balek P, Ballabene E, Balli F, Baltes LM, Balunas WK, Balz J, Banas E, Bandieramonte M, Bandyopadhyay A, Bansal S, Barak L, Barberio EL, Barberis D, Barbero M, Barbour G, Barends KN, Barillari T, Barisits MS, Barkeloo J, Barklow T, Barnett RM, Baron P, Moreno DAB, Baroncelli A, Barone G, Barr AJ, Navarro LB, Barreiro F, Guimarães da Costa JB, Barron U, Teixeira MGB, Barsov S, Bartels F, Bartoldus R, Barton AE, Bartos P, Basalaev A, Basan A, Baselga M, Bashta I, Bassalat A, Basso MJ, Basson CR, Bates RL, Batlamous S, Batley JR, Batool B, Battaglia M, Bauce M, Bauer P, Bayirli A, Beacham JB, Beau T, Beauchemin PH, Becherer F, Bechtle P, Beck HP, Becker K, Becot C, Beddall AJ, Bednyakov VA, Bee CP, Beemster LJ, Beermann TA, Begalli M, Begel M, Behera A, Behr JK, Beirao Da Cruz E Silva C, Beirer JF, Beisiegel F, Belfkir M, Bella G, Bellagamba L, Bellerive A, Bellos P, Beloborodov K, Belotskiy K, Belyaev NL, Benchekroun D, Bendebba F, Benhammou Y, Benjamin DP, Benoit M, Bensinger JR, Bentvelsen S, Beresford L, Beretta M, Berge D, Bergeaas Kuutmann E, Berger N, Bergmann B, Beringer J, Berlendis S, Bernardi G, Bernius C, Bernlochner FU, Berry T, Berta P, Berthold A, Bertram IA, Bylund OB, Bethke S, Betti A, Bevan AJ, Bhamjee M, Bhatta S, Bhattacharya DS, Bhattarai P, Bhopatkar VS, Bi R, Bi R, Bianchi RM, Biebel O, Bielski R, Biglietti M, Billoud TRV, Bindi M, Bingul A, Bini C, Biondi S, Biondini A, Birch-sykes CJ, Bird GA, Birman M, Bisanz T, Biswas D, Bitadze A, Bjørke K, Bloch I, Blocker C, Blue A, Blumenschein U, Blumenthal J, Bobbink GJ, Bobrovnikov VS, Boehler M, Bogavac D, Bogdanchikov AG, Bohm C, Boisvert V, Bokan P, Bold T, Bomben M, Bona M, Boonekamp M, Booth CD, Borbély AG, Borecka-Bielska HM, Borgna LS, Borissov G, Bortoletto D, Boscherini D, Bosman M, Sola JDB, Bouaouda K, Boudreau J, Bouhova-Thacker EV, Boumediene D, Bouquet R, Boveia A, Boyd J, Boye D, Boyko IR, Bracinik J, Brahimi N, Brandt G, Brandt O, Braren F, Brau B, Brau JE, Madden WDB, Brendlinger K, Brener R, Brenner L, Brenner R, Bressler S, Brickwedde B, Britton D, Britzger D, Brock I, Brooijmans G, Brooks WK, Brost E, de Renstrom PAB, Brüers B, Bruncko D, Bruni A, Bruni G, Bruschi M, Bruscino N, Bryngemark L, Buanes T, Buat Q, Buchholz P, Buckley AG, Budagov IA, Bugge MK, Bulekov O, Bullard BA, Burdin S, Burgard CD, Burger AM, Burghgrave B, Burr JTP, Burton CD, Burzynski JC, Busch EL, Büscher V, Bussey PJ, Butler JM, Buttar CM, Butterworth JM, Buttinger W, Vazquez CJB, Buzykaev AR, Cabras G, Urbán SC, Caforio D, Cai H, Cai Y, Cairo VMM, Cakir O, Calace N, Calafiura P, Calderini G, Calfayan P, Callea G, Caloba LP, Calvet D, Calvet S, Calvet TP, Calvetti M, Toro RC, Camarda S, Munoz DC, Camarri P, Camerlingo MT, Cameron D, Camincher C, Campanelli M, Camplani A, Canale V, Canesse A, Bret MC, Cantero J, Cao Y, Capocasa F, Capua M, Carbone A, Cardarelli R, Cardenas JCJ, Cardillo F, Carli T, Carlino G, Carlson BT, Carlson EM, Carminati L, Carnesale M, Caron S, Carquin E, Carrá S, Carratta G, Argos FC, Carter JWS, Carter TM, Casado MP, Casha AF, Castiglia EG, Castillo FL, Garcia LC, Gimenez VC, Castro NF, Catinaccio A, Catmore JR, Cavaliere V, Cavalli N, Cavasinni V, Celebi E, Celli F, Centonze MS, Cerny K, Cerqueira AS, Cerri A, Cerrito L, Cerutti F, Cervelli A, Cetin SA, Chadi Z, Chakraborty D, Chala M, Chan J, Chan WS, Chan WY, Chapman JD, Chargeishvili B, Charlton DG, Charman TP, Chatterjee M, Chekanov S, Chekulaev SV, Chelkov GA, Chen A, Chen B, Chen B, Chen C, Chen H, Chen H, Chen J, Chen J, Chen S, Chen SJ, Chen X, Chen X, Chen Y, Cheng CL, Cheng HC, Cheplakov A, Cheremushkina E, Cherepanova E, El Moursli RC, Cheu E, Cheung K, Chevalier L, Chiarella V, Chiarelli G, Chiodini G, Chisholm AS, Chitan A, Chiu YH, Chizhov MV, Choi K, Chomont AR, Chou Y, Chow EYS, Chowdhury T, Christopher LD, Chu KL, Chu MC, Chu X, Chudoba J, Chwastowski JJ, Cieri D, Ciesla KM, Cindro V, Ciocio A, Cirotto F, Citron ZH, Citterio M, Ciubotaru DA, Ciungu BM, Clark A, Clark PJ, Columbie JMC, Clawson SE, Clement C, Clercx J, Clissa L, Coadou Y, Cobal M, Coccaro A, Barrue RFC, De Sa RCL, Coelli S, Cohen H, Coimbra AEC, Cole B, Collot J, Muiño PC, Connell MP, Connell SH, Connelly IA, Conroy EI, Conventi F, Cooke HG, Cooper-Sarkar AM, Cormier F, Corpe LD, Corradi M, Corrigan EE, Corriveau F, Cortes-Gonzalez A, Costa MJ, Costanza F, Costanzo D, Cote BM, Cowan G, Cowley JW, Cranmer K, Crépé-Renaudin S, Crescioli F, Cristinziani M, Cristoforetti M, Croft V, Crosetti G, Cueto A, Donszelmann TC, Cui H, Cui Z, Cukierman AR, Cunningham WR, Curcio F, Czodrowski P, Czurylo MM, Da Cunha Sargedas De Sousa MJ, Pinto JVDF, Da Via C, Dabrowski W, Dado T, Dahbi S, Dai T, Dallapiccola C, Dam M, D’amen G, D’Amico V, Damp J, Dandoy JR, Daneri MF, Danninger M, Dao V, Darbo G, Darmora S, Das SJ, Dattagupta A, D’Auria S, David C, Davidek T, Davis DR, Davis-Purcell B, Dawson I, De K, De Asmundis R, De Beurs M, De Castro S, De Groot N, de Jong P, De la Torre H, De Maria A, De Salvo A, De Sanctis U, De Santo A, De Regie JBDV, Dedovich DV, Degens J, Deiana AM, Del Corso F, Del Peso J, Del Rio F, Deliot F, Delitzsch CM, Della Pietra M, Della Volpe D, Dell’Acqua A, Dell’Asta L, Delmastro M, Delsart PA, Demers S, Demichev M, Denisov SP, D’Eramo L, Derendarz D, Derue F, Dervan P, Desch K, Dette K, Deutsch C, Deviveiros PO, Di Bello FA, Di Ciaccio A, Di Ciaccio L, Di Domenico A, Donato CD, Di Girolamo A, Di Gregorio G, Di Luca A, Di Micco B, Di Nardo R, Diaconu C, Dias FA, Do Vale TD, Diaz MA, Capriles FGD, Didenko M, Diehl EB, Diehl L, Cornell SD, Pardos CD, Dimitriadi C, Dimitrievska A, Ding W, Dingfelder J, Dinu IM, Dittmeier SJ, Dittus F, Djama F, Djobava T, Djuvsland JI, Dodsworth D, Doglioni C, Dolejsi J, Dolezal Z, Donadelli M, Dong B, Donini J, D’Onofrio A, D’Onofrio M, Dopke J, Doria A, Dova MT, Doyle AT, Draguet MA, Drechsler E, Dreyer E, Drivas-koulouris I, Drobac AS, Du D, du Pree TA, Dubinin F, Dubovsky M, Duchovni E, Duckeck G, Ducu OA, Duda D, Dudarev A, D’uffizi M, Duflot L, Dührssen M, Dülsen C, Dumitriu AE, Dunford M, Dungs S, Dunne K, Duperrin A, Yildiz HD, Düren M, Durglishvili A, Dwyer BL, Dyckes GI, Dyndal M, Dysch S, Dziedzic BS, Earnshaw ZO, Eckerova B, Eggleston MG, Egidio Purcino De Souza E, Ehrke LF, Eigen G, Einsweiler K, Ekelof T, Ekman PA, El Ghazali Y, El Jarrari H, El Moussaouy A, Ellajosyula V, Ellert M, Ellinghaus F, Elliot AA, Ellis N, Elmsheuser J, Elsing M, Emeliyanov D, Emerman A, Enari Y, Ene I, Epari S, Erdmann J, Ereditato A, Erland PA, Errenst M, Escalier M, Escobar C, Etzion E, Evans G, Evans H, Evans MO, Ezhilov A, Ezzarqtouni S, Fabbri F, Fabbri L, Facini G, Fadeyev V, Fakhrutdinov RM, Falciano S, Falke PJ, Falke S, Faltova J, Fan Y, Fang Y, Fanourakis G, Fanti M, Faraj M, Farbin A, Farilla A, Farooque T, Farrington SM, Fassi F, Fassouliotis D, Giannelli MF, Fawcett WJ, Fayard L, Fedin OL, Fedotov G, Feickert M, Feligioni L, Fell A, Fellers DE, Feng C, Feng M, Fenton MJ, Fenyuk AB, Ferencz L, Ferguson SW, Pretel J, Ferrando J, Ferrari A, Ferrari P, Ferrari R, Ferrere D, Ferretti C, Fiedler F, Filipčič A, Filmer EK, Filthaut F, Fiolhais MCN, Fiorini L, Fischer F, Fisher WC, Fitschen T, Fleck I, Fleischmann P, Flick T, Flores L, Flores M, Castillo LRF, Follega FM, Fomin N, Foo JH, Forland BC, Formica A, Forti AC, Fortin E, Fortman AW, Foti MG, Fountas L, Fournier D, Fox H, Francavilla P, Francescato S, Franchini M, Franchino S, Francis D, Franco L, Franconi L, Franklin M, Frattari G, Freegard AC, Freeman PM, Freund WS, Fritzsche N, Froch A, Froidevaux D, Frost JA, Fu Y, Fujimoto M, Torregrosa EF, Fuster J, Gabrielli A, Gabrielli A, Gadow P, Gagliardi G, Gagnon LG, Gallardo GE, Gallas EJ, Gallop BJ, Goni RG, Gan KK, Ganguly S, Gao J, Gao Y, Walls FMG, Garcia B, García C, Navarro JEG, Pascual JAG, Garcia-Sciveres M, Gardner RW, Garg D, Garg RB, Gargiulo S, Garner CA, Garonne V, Gasiorowski SJ, Gaspar P, Gaudio G, Gautam V, Gauzzi P, Gavrilenko IL, Gavrilyuk A, Gay C, Gaycken G, Gazis EN, Geanta AA, Gee CM, Geisen J, Geisen M, Gemme C, Genest MH, Gentile S, George S, George WF, Geralis T, Gerlach LO, Gessinger-Befurt P, Bostanabad MG, Ghneimat M, Ghosal A, Ghosh A, Ghosh A, Giacobbe B, Giagu S, Giangiacomi N, Giannetti P, Giannini A, Gibson SM, Gignac M, Gil DT, Gilbert AK, Gilbert BJ, Gillberg D, Gilles G, Gillwald NEK, Ginabat L, Gingrich DM, Giordani MP, Giraud PF, Giugliarelli G, Giugni D, Giuli F, Gkialas I, Gladilin LK, Glasman C, Gledhill GR, Glisic M, Gnesi I, Go Y, Goblirsch-Kolb M, Godin D, Goldfarb S, Golling T, Gololo MGD, Golubkov D, Gombas JP, Gomes A, Gomes Da Silva G, Gomez Delegido AJ, Goncalves Gama R, Gonçalo R, Gonella G, Gonella L, Gongadze A, Gonnella F, Gonski JL, González de la Hoz S, Fernandez SG, Gonzalez Lopez R, Renteria CG, Suarez RG, Gonzalez-Sevilla S, Rodriguez GRG, González Andana RY, Goossens L, Gorasia NA, Gorbounov PA, Gorini B, Gorini E, Gorišek A, Goshaw AT, Gostkin MI, Gottardo CA, Gouighri M, Goumarre V, Goussiou AG, Govender N, Goy C, Grabowska-Bold I, Graham K, Gramstad E, Grancagnolo S, Grandi M, Gratchev V, Gravila PM, Gravili FG, Gray HM, Greco M, Grefe C, Gregor IM, Grenier P, Grieco C, Grillo AA, Grimm K, Grinstein S, Grivaz JF, Gross E, Grosse-Knetter J, Grud C, Grummer A, Grundy JC, Guan L, Guan W, Gubbels C, Rojas JGRG, Guerrieri G, Guescini F, Gugel R, Guhit JAM, Guida A, Guillemin T, Guilloton E, Guindon S, Guo F, Guo J, Guo L, Guo Y, Gupta R, Gurbuz S, Gurdasani SS, Gustavino G, Guth M, Gutierrez P, Zagazeta LFG, Gutschow C, Guyot C, Gwenlan C, Gwilliam CB, Haaland ES, Haas A, Habedank M, Haber C, Hadavand HK, Hadef A, Hadzic S, Haleem M, Haley J, Hall JJ, Hallewell GD, Halser L, Hamano K, Hamdaoui H, Hamer M, Hamity GN, Han J, Han K, Han L, Han L, Han S, Han YF, Hanagaki K, Hance M, Hangal DA, Hank MD, Hankache R, Hansen JB, Hansen JD, Hansen PH, Hara K, Harada D, Harenberg T, Harkusha S, Harris YT, Harrison NM, Harrison PF, Hartman NM, Hartmann NM, Hasegawa Y, Hasib A, Haug S, Hauser R, Havranek M, Hawkes CM, Hawkings RJ, Hayashida S, Hayden D, Hayes C, Hayes RL, Hays CP, Hays JM, Hayward HS, He F, He Y, He Y, Heath MP, Hedberg V, Heggelund AL, Hehir ND, Heidegger C, Heidegger KK, Heidorn WD, Heilman J, Heim S, Heim T, Heinlein JG, Heinrich JJ, Heinrich L, Hejbal J, Helary L, Held A, Hellesund S, Helling CM, Hellman S, Helsens C, Henderson RCW, Henkelmann L, Correia AMH, Herde H, Jiménez YH, Herr H, Herrmann MG, Herrmann T, Herten G, Hertenberger R, Hervas L, Hessey NP, Hibi H, Higón-Rodriguez E, Hillier SJ, Hinchliffe I, Hinterkeuser F, Hirose M, Hirose S, Hirschbuehl D, Hitchings TG, Hiti B, Hobbs J, Hobincu R, Hod N, Hodgkinson MC, Hodkinson BH, Hoecker A, Hofer J, Hohn D, Holm T, Holzbock M, Hommels LBAH, Honan BP, Hong J, Hong TM, Hong Y, Honig JC, Hönle A, Hooberman BH, Hopkins WH, Horii Y, Hou S, Howard AS, Howarth J, Hoya J, Hrabovsky M, Hrynevich A, Hryn’ova T, Hsu PJ, Hsu SC, Hu Q, Hu YF, Huang DP, Huang S, Huang X, Huang Y, Huang Y, Huang Z, Hubacek Z, Huebner M, Huegging F, Huffman TB, Huhtinen M, Huiberts SK, Hulsken R, Huseynov N, Huston J, Huth J, Hyneman R, Hyrych S, Iacobucci G, Iakovidis G, Ibragimov I, Iconomidou-Fayard L, Iengo P, Iguchi R, Iizawa T, Ikegami Y, Ilg A, Ilic N, Imam H, Ingebretsen Carlson T, Introzzi G, Iodice M, Ippolito V, Ishino M, Islam W, Issever C, Istin S, Ito H, Ponce JMI, Iuppa R, Ivina A, Izen JM, Izzo V, Jacka P, Jackson P, Jacobs RM, Jaeger BP, Jagfeld CS, Jäkel G, Jakobs K, Jakoubek T, Jamieson J, Janas KW, Jarlskog G, Jaspan AE, Javůrek T, Javurkova M, Jeanneau F, Jeanty L, Jejelava J, Jenni P, Jessiman CE, Jézéquel S, Jia J, Jia X, Jia X, Jia Z, Jiang Y, Jiggins S, Pena JJ, Jin S, Jinaru A, Jinnouchi O, Jivan H, Johansson P, Johns KA, Johnson CA, Jones DM, Jones E, Jones P, Jones RWL, Jones TJ, Jovicevic J, Ju X, Junggeburth JJ, Rozas AJ, Kabana S, Kaczmarska A, Kado M, Kagan H, Kagan M, Kahn A, Kahn A, Kahra C, Kaji T, Kajomovitz E, Kakati N, Kalderon CW, Kamenshchikov A, Kang NJ, Kano Y, Kar D, Karava K, Kareem MJ, Karentzos E, Karkanias I, Karpov SN, Karpova ZM, Kartvelishvili V, Karyukhin AN, Kasimi E, Kato C, Katzy J, Kaur S, Kawade K, Kawagoe K, Kawaguchi T, Kawamoto T, Kawamura G, Kay EF, Kaya FI, Kazakos S, Kazanin VF, Ke Y, Keaveney JM, Keeler R, Kehris GV, Keller JS, Kelly AS, Kelsey D, Kempster JJ, Kendrick J, Kennedy KE, Kepka O, Kerridge BP, Kersten S, Kerševan BP, Keszeghova L, Haghighat SK, Khandoga M, Khanov A, Kharlamov AG, Kharlamova T, Khoda EE, Khoo TJ, Khoriauli G, Khubua J, Khwaira YAR, Kiehn M, Kilgallon A, Kim DW, Kim E, Kim YK, Kimura N, Kirchhoff A, Kirchmeier D, Kirfel C, Kirk J, Kiryunin AE, Kishimoto T, Kisliuk DP, Kitsaki C, Kivernyk O, Klassen M, Klein C, Klein L, Klein MH, Klein M, Klein U, Klimek P, Klimentov A, Klimpel F, Klingl T, Klioutchnikova T, Klitzner FF, Kluit P, Kluth S, Kneringer E, Knight TM, Knue A, Kobayashi D, Kobayashi R, Kocian M, Kodama T, Kodyš P, Koeck DM, Koenig PT, Koffas T, Köhler NM, Kolb M, Koletsou I, Komarek T, Köneke K, Kong AXY, Kono T, Konstantinidis N, Konya B, Kopeliansky R, Koperny S, Korcyl K, Kordas K, Koren G, Korn A, Korn S, Korolkov I, Korotkova N, Kortman B, Kortner O, Kortner S, Kostecka WH, Kostyukhin VV, Kotsokechagia A, Kotwal A, Koulouris A, Kourkoumeli-Charalampidi A, Kourkoumelis C, Kourlitis E, Kovanda O, Kowalewski R, Kozanecki W, Kozhin AS, Kramarenko VA, Kramberger G, Kramer P, Krasny MW, Krasznahorkay A, Kremer JA, Kresse T, Kretzschmar J, Kreul K, Krieger P, Krieter F, Krishnamurthy S, Krishnan A, Krivos M, Krizka K, Kroeninger K, Kroha H, Kroll J, Kroll J, Krowpman KS, Kruchonak U, Krüger H, Krumnack N, Kruse MC, Krzysiak JA, Kubota A, Kuchinskaia O, Kuday S, Kuechler D, Kuechler JT, Kuehn S, Kuhl T, Kukhtin V, Kulchitsky Y, Kuleshov S, Kumar M, Kumari N, Kuna M, Kupco A, Kupfer T, Kupich A, Kuprash O, Kurashige H, Kurchaninov LL, Kurochkin YA, Kurova A, Kuwertz ES, Kuze M, Kvam AK, Kvita J, Kwan T, Kwok KW, Lacasta C, Lacava F, Lacker H, Lacour D, Lad NN, Ladygin E, Laforge B, Lagouri T, Lai S, Lakomiec IK, Lalloue N, Lambert JE, Lammers S, Lampl W, Lampoudis C, Lancaster AN, Lançon E, Landgraf U, Landon MPJ, Lang VS, Langenberg RJ, Lankford AJ, Lanni F, Lantzsch K, Lanza A, Lapertosa A, Laporte JF, Lari T, Manghi FL, Lassnig M, Latonova V, Lau TS, Laudrain A, Laurier A, Lawlor SD, Lawrence Z, Lazzaroni M, Le B, Leban B, Lebedev A, LeBlanc M, LeCompte T, Ledroit-Guillon F, Lee ACA, Lee GR, Lee L, Lee SC, Lee S, Leeuw LL, Lefebvre HP, Lefebvre M, Leggett C, Lehmann K, Miotto GL, Leight WA, Leisos A, Leite MAL, Leitgeb CE, Leitner R, Leney KJC, Lenz T, Leone S, Leonidopoulos C, Leopold A, Leroy C, Les R, Lester CG, Levchenko M, Levêque J, Levin D, Levinson LJ, Lewicki MP, Lewis DJ, Li B, Li B, Li C, Li CQ, Li H, Li H, Li H, Li J, Li K, Li L, Li M, Li QY, Li S, Li T, Li X, Li Z, Li Z, Li Z, Li Z, Liang Z, Liberatore M, Liberti B, Lie K, Marin JL, Lin K, Linck RA, Lindley RE, Lindon JH, Linss A, Lipeles E, Lipniacka A, Liss TM, Lister A, Little JD, Liu B, Liu BX, Liu D, Liu JB, Liu JKK, Liu K, Liu M, Liu MY, Liu P, Liu Q, Liu X, Liu Y, Liu Y, Liu YL, Liu YW, Livan M, Merino JL, Lloyd SL, Lobodzinska EM, Loch P, Loffredo S, Lohse T, Lohwasser K, Lokajicek M, Long JD, Longarini I, Longo L, Longo R, Paz IL, Solis AL, Lorenz J, Martinez NL, Lory AM, Lösle A, Lou X, Lou X, Lounis A, Love J, Love PA, Bahilo JJL, Lu G, Lu M, Lu S, Lu YJ, Lubatti HJ, Luci C, Alves FLL, Lucotte A, Luehring F, Luise I, Lukianchuk O, Lundberg O, Lund-Jensen B, Luongo NA, Lutz MS, Lynn D, Lyons H, Lysak R, Lytken E, Lyu F, Lyubushkin V, Lyubushkina T, Ma H, Ma LL, Ma Y, Mac Donell DM, Maccarrone G, MacDonald JC, Madar R, Mader WF, Maeda J, Maeno T, Maerker M, Magerl V, Magro J, Maguire H, Mahon DJ, Maidantchik C, Maio A, Maj K, Majersky O, Majewski S, Makovec N, Maksimovic V, Malaescu B, Malecki P, Maleev VP, Malek F, Malito D, Mallik U, Malone C, Maltezos S, Malyukov S, Mamuzic J, Mancini G, Manco G, Mandalia JP, Mandić I, de Andrade Filho LM, Maniatis IM, Manisha M, Ramos JM, Mankad DC, Mankinen KH, Mann A, Manousos A, Mansoulie B, Manzoni S, Marantis A, Marchiori G, Marcisovsky M, Marcoccia L, Marcon C, Marinescu M, Marjanovic M, Marshall Z, Marti-Garcia S, Martin TA, Martin VJ, Martin dit Latour B, Martinelli L, Martinez M, Agullo PM, Outschoorn VIM, Suarez PM, Martin-Haugh S, Martoiu VS, Martyniuk AC, Marzin A, Maschek SR, Masetti L, Mashimo T, Masik J, Maslennikov AL, Massa L, Massarotti P, Mastrandrea P, Mastroberardino A, Masubuchi T, Mathisen T, Matic A, Matsuzawa N, Maurer J, Maček B, Maximov DA, Mazini R, Maznas I, Mazza M, Mazza SM, Mc Ginn C, Mc Gowan JP, Mc Kee SP, McCarthy TG, McCormack WP, McDonald EF, McDougall AE, Mcfayden JA, Mchedlidze G, Mckenzie RP, Mclachlan TC, Mclaughlin DJ, McLean KD, McMahon SJ, McNamara PC, McPherson RA, Mdhluli JE, Meehan S, Megy T, Mehlhase S, Mehta A, Meirose B, Melini D, Garcia BRM, Melo AH, Meloni F, Gouveia EDM, Da Costa AMMJ, Meng HY, Meng L, Menke S, Mentink M, Meoni E, Merlassino C, Merola L, Meroni C, Merz G, Meshkov O, Meshreki JKR, Metcalfe J, Mete AS, Meyer C, Meyer JP, Michetti M, Middleton RP, Mijović L, Mikenberg G, Mikestikova M, Mikuž M, Mildner H, Milic A, Milke CD, Miller DW, Miller LS, Milov A, Milstead DA, Min T, Minaenko AA, Minashvili IA, Mince L, Mincer AI, Mindur B, Mineev M, Minegishi Y, Mino Y, Mir LM, Lopez MM, Mironova M, Mitani T, Mitra A, Mitsou VA, Miu O, Miyagawa PS, Miyazaki Y, Mizukami A, Mjörnmark JU, Mkrtchyan T, Mlynarikova M, Moa T, Mobius S, Mochizuki K, Moder P, Mogg P, Mohammed AF, Mohapatra S, Mokgatitswane G, Mondal B, Mondal S, Mönig K, Monnier E, Romero LM, Berlingen JM, Montella M, Monticelli F, Morange N, De Carvalho ALM, Llácer MM, Martinez CM, Morettini P, Morgenstern S, Morii M, Morinaga M, Morisbak V, Morley AK, Morodei F, Morvaj L, Moschovakos P, Moser B, Mosidze M, Moskalets T, Moskvitina P, Moss J, Moyse EJW, Muanza S, Mueller J, Muenstermann D, Müller R, Mullier GA, Mullin JJ, Mungo DP, Martinez JLM, Perez DM, Sanchez FJM, Murin M, Murray WJ, Murrone A, Muse JM, Muškinja M, Mwewa C, Myagkov AG, Myers AJ, Myers AA, Myers G, Myska M, Nachman BP, Nackenhorst O, Nag A, Nagai K, Nagano K, Nagle JL, Nagy E, Nairz AM, Nakahama Y, Nakamura K, Nanjo H, Narayan R, Narayanan EA, Naryshkin I, Naseri M, Nass C, Navarro G, Navarro-Gonzalez J, Nayak R, Nechaeva PY, Nechansky F, Neep TJ, Negri A, Negrini M, Nellist C, Nelson C, Nelson K, Nemecek S, Nessi M, Neubauer MS, Neuhaus F, Neundorf J, Newhouse R, Newman PR, Ng CW, Ng YS, Ng YWY, Ngair B, Nguyen HDN, Nickerson RB, Nicolaidou R, Nielsen J, Niemeyer M, Nikiforou N, Nikolaenko V, Nikolic-Audit I, Nikolopoulos K, Nilsson P, Nindhito HR, Nisati A, Nishu N, Nisius R, Nitschke JE, Nkadimeng EK, Rosende SJN, Nobe T, Noel DL, Noguchi Y, Nommensen T, Nomura MA, Norfolk MB, Norisam RRB, Norman BJ, Novak J, Novak T, Novgorodova O, Novotny L, Novotny R, Nozka L, Ntekas K, Nurse E, Oakham FG, Ocariz J, Ochi A, Ochoa I, Oerdek S, Ogrodnik A, Oh A, Ohm CC, Oide H, Oishi R, Ojeda ML, Okazaki Y, O’Keefe MW, Okumura Y, Olariu A, Seabra LFO, Pino SAO, Damazio DO, Goncalves DO, Oliver JL, Olsson MJR, Olszewski A, Olszowska J, Öncel ÖO, O’Neil DC, O’Neill AP, Onofre A, Onyisi PUE, Oreglia MJ, Orellana GE, Orestano D, Orlando N, Orr RS, O’Shea V, Ospanov R, Otero y Garzon G, Otono H, Ott PS, Ottino GJ, Ouchrif M, Ouellette J, Ould-Saada F, Owen M, Owen RE, Oyulmaz KY, Ozcan VE, Ozturk N, Ozturk S, Pacalt J, Pacey HA, Pachal K, Pages AP, Aranda CP, Padovano G, Griso SP, Palacino G, Palazzo A, Palazzo S, Palestini S, Palka M, Pan J, Pan T, Panchal DK, Pandini CE, Vazquez JGP, Pang H, Pani P, Panizzo G, Paolozzi L, Papadatos C, Parajuli S, Paramonov A, Paraskevopoulos C, Hernandez DP, Park TH, Parker MA, Parodi F, Parrish EW, Parrish VA, Parsons JA, Parzefall U, Dias BP, Dominguez LP, Pascuzzi VR, Pasquali F, Pasqualucci E, Passaggio S, Pastore F, Pasuwan P, Pater JR, Patton J, Pauly T, Pearkes J, Pedersen M, Pedro R, Peleganchuk SV, Penc O, Peng C, Peng H, Penski KE, Penzin M, Peralva BS, Peixoto APP, Sanchez LP, Perepelitsa DV, Codina EP, Perganti M, Perini L, Pernegger H, Perrella S, Perrevoort A, Perrin O, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petousis V, Petridou C, Petrukhin A, Pettee M, Pettersson NE, Petukhov A, Petukhova K, Peyaud A, Pezoa R, Pezzotti L, Pezzullo G, Pham T, Phillips PW, Phipps MW, Piacquadio G, Pianori E, Piazza F, Piegaia R, Pietreanu D, Pilkington AD, Pinamonti M, Pinfold JL, Pereira BCP, Donaldson CP, Pizzi DA, Pizzimento L, Pizzini A, Pleier MA, Plesanovs V, Pleskot V, Plotnikova E, Poddar G, Poettgen R, Poggi R, Poggioli L, Pogrebnyak I, Pohl D, Pokharel I, Polacek S, Polesello G, Poley A, Polifka R, Polini A, Pollard CS, Pollock ZB, Polychronakos V, Ponomarenko D, Pontecorvo L, Popa S, Popeneciu GA, Quintero DMP, Pospisil S, Postolache P, Potamianos K, Potrap IN, Potter CJ, Potti H, Poulsen T, Poveda J, Pownall G, Astigarraga MEP, Ibanez AP, Prapa MM, Price D, Primavera M, Martin MAP, Proffitt ML, Proklova N, Prokofiev K, Proto G, Protopopescu S, Proudfoot J, Przybycien M, Puddefoot JE, Pudzha D, Puzo P, Pyatiizbyantseva D, Qian J, Qin Y, Qiu T, Quadt A, Queitsch-Maitland M, Rabanal Bolanos G, Rafanoharana D, Ragusa F, Rainbolt JL, Raine JA, Rajagopalan S, Ramakoti E, Ran K, Raskina V, Rassloff DF, Rave S, Ravina B, Ravinovich I, Raymond M, Read AL, Readioff NP, Rebuzzi DM, Redlinger G, Reeves K, Reidelsturz JA, Reikher D, Reiss A, Rej A, Rembser C, Renardi A, Renda M, Rendel MB, Rennie AG, Resconi S, Ressegotti M, Resseguie ED, Rettie S, Reynolds B, Reynolds E, Estabragh MR, Rezanova OL, Reznicek P, Ricci E, Richter R, Richter S, Richter-Was E, Ridel M, Rieck P, Riedler P, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Rinn TT, Rinnagel MP, Ripellino G, Riu I, Rivadeneira P, Vergara JCR, Rizatdinova F, Rizvi E, Rizzi C, Roberts BA, Roberts BR, Robertson SH, Robin M, Robinson D, Robles Gajardo CM, Manzano MR, Robson A, Rocchi A, Roda C, Rodriguez Bosca S, Garcia YR, Rodriguez AR, Rodríguez Vera AM, Roe S, Roemer JT, Roepe-Gier AR, Roggel J, Røhne O, Rojas RA, Roland B, Roland CPA, Roloff J, Romaniouk A, Romano E, Romano M, Hernandez ACR, Rompotis N, Roos L, Rosati S, Rosser BJ, Rossi E, Rossi E, Rossi LP, Rossini L, Rosten R, Rotaru M, Rottler B, Rousseau D, Rousso D, Rovelli G, Roy A, Rozanov A, Rozen Y, Ruan X, Jimenez AR, Ruby AJ, Ruggeri TA, Rühr F, Ruiz-Martinez A, Rummler A, Rurikova Z, Rusakovich NA, Russell HL, Rutherfoord JP, Rüttinger EM, Rybacki K, Rybar M, Rye EB, Ryzhov A, Iglesias JAS, Sabatini P, Sabetta L, Sadrozinski HFW, Tehrani FS, Samani BS, Safdari M, Saha S, Sahinsoy M, Saimpert M, Saito M, Saito T, Salamani D, Salamanna G, Salnikov A, Salt J, Salas AS, Salvatore D, Salvatore F, Salzburger A, Sammel D, Sampsonidis D, Sampsonidou D, Sánchez J, Pineda AS, Sebastian VS, Sandaker H, Sander CO, Sandesara JA, Sandhoff M, Sandoval C, Sankey DPC, Sansoni A, Santi L, Santoni C, Santos H, Santpur SN, Santra A, Saoucha KA, Saraiva JG, Sardain J, Sasaki O, Sato K, Sauer C, Sauerburger F, Sauvan E, Savard P, Sawada R, Sawyer C, Sawyer L, Galvan IS, Sbarra C, Sbrizzi A, Scanlon T, Schaarschmidt J, Schacht P, Schaefer D, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Schanet E, Scharf C, Schegelsky VA, Scheirich D, Schenck F, Schernau M, Scheulen C, Schiavi C, Schillaci ZM, Schioppa EJ, Schioppa M, Schlag B, Schleicher KE, Schlenker S, Schmieden K, Schmitt C, Schmitt S, Schoeffel L, Schoening A, Scholer PG, Schopf E, Schott M, Schovancova J, Schramm S, Schroeder F, Schultz-Coulon HC, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schwemling P, Schwienhorst R, Sciandra A, Sciolla G, Scuri F, Scutti F, Sebastiani CD, Sedlaczek K, Seema P, Seidel SC, Seiden A, Seidlitz BD, Seiss T, Seitz C, Seixas JM, Sekhniaidze G, Sekula SJ, Selem L, Semprini-Cesari N, Sen S, Sengupta D, Senthilkumar V, Serin L, Serkin L, Sessa M, Severini H, Sevova S, Sforza F, Sfyrla A, Shabalina E, Shaheen R, Shahinian JD, Shaikh NW, Renous DS, Shan LY, Shapiro M, Sharma A, Sharma AS, Sharma P, Sharma S, Shatalov PB, Shaw K, Shaw SM, Shen Q, Sherwood P, Shi L, Shimmin CO, Shimogama Y, Shinner JD, Shipsey IPJ, Shirabe S, Shiyakova M, Shlomi J, Shochet MJ, Shojaii J, Shope DR, Shrestha S, Shrif EM, Shroff MJ, Sicho P, Sickles AM, Haddad ES, Sidiropoulou O, Sidoti A, Siegert F, Sijacki D, Sikora R, Sili F, Silva JM, Oliveira MVS, Silverstein SB, Simion S, Simoniello R, Simpson EL, Simpson ND, Simsek S, Sindhu S, Sinervo P, Sinetckii V, Singh S, Singh S, Sinha S, Sinha S, Sioli M, Siral I, Sivoklokov SY, Sjölin J, Skaf A, Skorda E, Skubic P, Slawinska M, Smakhtin V, Smart BH, Smiesko J, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith AC, Smith EA, Smith HA, Smith JL, Smith R, Smizanska M, Smolek K, Smykiewicz A, Snesarev AA, Snoek HL, Snyder S, Sobie R, Soffer A, Sanchez CAS, Soldatov EY, Soldevila U, Solodkov AA, Solomon S, Soloshenko A, Solovieva K, Solovyanov OV, Solovyev V, Sommer P, Sonay A, Song WY, Sopczak A, Sopio AL, Sopkova F, Sothilingam V, Sottocornola S, Soualah R, Soumaimi Z, South D, Spagnolo S, Spalla M, Spanò F, Sperlich D, Spigo G, Spina M, Spinali S, Spiteri DP, Spousta M, Staats EJ, Stabile A, Stamen R, Stamenkovic M, Stampekis A, Standke M, Stanecka E, Stanislaus B, Stanitzki MM, Stankaityte M, Stapf B, Starchenko EA, Stark GH, Stark J, Starko DM, Staroba P, Starovoitov P, Stärz S, Staszewski R, Stavropoulos G, Steentoft J, Steinberg P, Steinhebel AL, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stevenson TJ, Stewart GA, Stockton MC, Stoicea G, Stolarski M, Stonjek S, Straessner A, Strandberg J, Strandberg S, Strauss M, Strebler T, Strizenec P, Ströhmer R, Strom DM, Strom LR, Stroynowski R, Strubig A, Stucci SA, Stugu B, Stupak J, Styles NA, Su D, Su S, Su W, Su X, Sugizaki K, Sulin VV, Sullivan MJ, Sultan DMS, Sultanaliyeva L, Sultansoy S, Sumida T, Sun S, Sun S, Gudnadottir OS, Sutton MR, Svatos M, Swiatlowski M, Swirski T, Sykora I, Sykora M, Sykora T, Ta D, Tackmann K, Taffard A, Tafirout R, Vargas JST, Taibah RHM, Takashima R, Takeda K, Takeva EP, Takubo Y, Talby M, Talyshev AA, Tam KC, Tamir NM, Tanaka A, Tanaka J, Tanaka R, Tanasini M, Tang J, Tao Z, Araya ST, Tapprogge S, Tarek Abouelfadl Mohamed A, Tarem S, Tariq K, Tarna G, Tartarelli GF, Tas P, Tasevsky M, Tassi E, Tate AC, Tateno G, Tayalati Y, Taylor GN, Taylor W, Teagle H, Tee AS, De Lima RT, Teixeira-Dias P, Teoh JJ, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Thaler A, Themistokleous N, Theveneaux-Pelzer T, Thielmann O, Thomas DW, Thomas JP, Thompson EA, Thompson PD, Thomson E, Thorpe EJ, Tian Y, Tikhomirov V, Tikhonov YA, Timoshenko S, Ting EXL, Tipton P, Tisserant S, Tlou SH, Tnourji A, Todome K, Todorova-Nova S, Todt S, Togawa M, Tojo J, Tokár S, Tokushuku K, Tombs R, Tomoto M, Tompkins L, Tornambe P, Torrence E, Torres H, Pastor ET, Toscani M, Tosciri C, Tovey DR, Traeet A, Trandafir IS, Trefzger T, Tricoli A, Trigger IM, Trincaz-Duvoid S, Trischuk DA, Trocmé B, Trofymov A, Troncon C, Truong L, Trzebinski M, Trzupek A, Tsai F, Tsai M, Tsiamis A, Tsiareshka PV, Tsigaridas S, Tsirigotis A, Tsiskaridze V, Tskhadadze EG, Tsopoulou M, Tsujikawa Y, Tsukerman II, Tsulaia V, Tsuno S, Tsur O, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tuna AN, Turchikhin S, Cakir IT, Turra R, Turtuvshin T, Tuts PM, Tzamarias S, Tzanis P, Tzovara E, Uchida K, Ukegawa F, Poblete PAU, Unal G, Unal M, Undrus A, Unel G, Uno K, Urban J, Urquijo P, Usai G, Ushioda R, Usman M, Uysal Z, Vacek V, Vachon B, Vadla KOH, Vafeiadis T, Valderanis C, Santurio EV, Valente M, Valentinetti S, Valero A, Vallier A, Ferrer JAV, Van Daalen TR, Van Gemmeren P, Van Stroud S, Van Vulpen I, Vanadia M, Vandelli W, Vandenbroucke M, Vandewall ER, Vannicola D, Vannoli L, Vari R, Varnes EW, Varni C, Varol T, Varouchas D, Varriale L, Varvell KE, Vasile ME, Vaslin L, Vasquez GA, Vazeille F, Schroeder TV, Veatch J, Vecchio V, Veen MJ, Veliscek I, Veloce LM, Veloso F, Veneziano S, Ventura A, Verbytskyi A, Verducci M, Vergis C, De Araujo MV, Verkerke W, Vermeulen JC, Vernieri C, Verschuuren PJ, Vessella M, Vesterbacka ML, Vetterli MC, Vgenopoulos A, Maira NV, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Vigani L, Villa M, Villaplana Perez M, Villhauer EM, Vilucchi E, Vincter MG, Virdee GS, Vishwakarma A, Vittori C, Vivarelli I, Vladimirov V, Voevodina E, Vogel F, Vokac P, Von Ahnen J, Von Toerne E, Vormwald B, Vorobel V, Vorobev K, Vos M, Vossebeld JH, Vozak M, Vozdecky L, Vranjes N, Vranjes Milosavljevic M, Vreeswijk M, Vuillermet R, Vujinovic O, Vukotic I, Wada S, Wagner C, Wagner W, Wahdan S, Wahlberg H, Wakasa R, Wakida M, Walbrecht VM, Walder J, Walker R, Walkowiak W, Wang AM, Wang AZ, Wang C, Wang C, Wang H, Wang J, Wang P, Wang RJ, Wang R, Wang R, Wang SM, Wang S, Wang T, Wang WT, Wang WX, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Z, Wang Z, Warburton A, Ward RJ, Warrack N, Watson AT, Watson MF, Watts G, Waugh BM, Webb AF, Weber C, Weber MS, Weber SA, Weber SM, Wei C, Wei Y, Weidberg AR, Weingarten J, Weirich M, Weiser C, Wells CJ, Wenaus T, Wendland B, Wengler T, Wenke NS, Wermes N, Wessels M, Whalen K, Wharton AM, White AS, White A, White MJ, Whiteson D, Wickremasinghe L, Wiedenmann W, Wiel C, Wielers M, Wieseotte N, Wiglesworth C, Wiik-Fuchs LAM, Wilbern DJ, Wilkens HG, Williams DM, Williams HH, Williams S, Willocq S, Windischhofer PJ, Winklmeier F, Winter BT, Wittgen M, Wobisch M, Wolf A, Wölker R, Wollrath J, Wolter MW, Wolters H, Wong VWS, Wongel AF, Worm SD, Wosiek BK, Woźniak KW, Wraight K, Wu J, Wu M, Wu SL, Wu X, Wu Y, Wu Z, Wuerzinger J, Wyatt TR, Wynne BM, Xella S, Xia L, Xia M, Xiang J, Xiao X, Xie M, Xie X, Xiong J, Xiotidis I, Xu D, Xu H, Xu L, Xu R, Xu T, Xu W, Xu Y, Xu Z, Xu Z, Yabsley B, Yacoob S, Yamaguchi N, Yamaguchi Y, Yamauchi H, Yamazaki T, Yamazaki Y, Yan J, Yan S, Yan Z, Yang HJ, Yang HT, Yang S, Yang T, Yang X, Yang X, Yang Y, Yang Z, Yao WM, Yap YC, Ye H, Ye J, Ye S, Ye X, Yeh Y, Yeletskikh I, Yexley MR, Yin P, Yorita K, Young CJS, Young C, Yuan M, Yuan R, Yue L, Yue X, Zaazoua M, Zabinski B, Zaid E, Zakareishvili T, Zakharchuk N, Zambito S, Zang J, Zanzi D, Zaplatilek O, Zeißner SV, Zeitnitz C, Zeng JC, Zenger DT, Zenin O, Ženiš T, Zenz S, Zerradi S, Zerwas D, Zhang B, Zhang DF, Zhang G, Zhang J, Zhang K, Zhang L, Zhang R, Zhang S, Zhang T, Zhang X, Zhang X, Zhang Z, Zhang Z, Zhao H, Zhao P, Zhao T, Zhao Y, Zhao Z, Zhemchugov A, Zheng Z, Zhong D, Zhou B, Zhou C, Zhou H, Zhou N, Zhou Y, Zhu CG, Zhu C, Zhu HL, Zhu H, Zhu J, Zhu Y, Zhu Y, Zhuang X, Zhukov K, Zhulanov V, Zimine NI, Zinsser J, Ziolkowski M, Živković L, Zoccoli A, Zoch K, Zorbas TG, Zormpa O, Zou W, Zwalinski L. A detailed map of Higgs boson interactions by the ATLAS experiment ten years after the discovery. Nature 2022; 607:52-59. [PMID: 35788192 PMCID: PMC9259483 DOI: 10.1038/s41586-022-04893-w] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Accepted: 05/23/2022] [Indexed: 11/16/2022]
Abstract
The standard model of particle physics1-4 describes the known fundamental particles and forces that make up our Universe, with the exception of gravity. One of the central features of the standard model is a field that permeates all of space and interacts with fundamental particles5-9. The quantum excitation of this field, known as the Higgs field, manifests itself as the Higgs boson, the only fundamental particle with no spin. In 2012, a particle with properties consistent with the Higgs boson of the standard model was observed by the ATLAS and CMS experiments at the Large Hadron Collider at CERN10,11. Since then, more than 30 times as many Higgs bosons have been recorded by the ATLAS experiment, enabling much more precise measurements and new tests of the theory. Here, on the basis of this larger dataset, we combine an unprecedented number of production and decay processes of the Higgs boson to scrutinize its interactions with elementary particles. Interactions with gluons, photons, and W and Z bosons-the carriers of the strong, electromagnetic and weak forces-are studied in detail. Interactions with three third-generation matter particles (bottom (b) and top (t) quarks, and tau leptons (τ)) are well measured and indications of interactions with a second-generation particle (muons, μ) are emerging. These tests reveal that the Higgs boson discovered ten years ago is remarkably consistent with the predictions of the theory and provide stringent constraints on many models of new phenomena beyond the standard model.
Collapse
|
178
|
Handique U, Cao Y, Wang D, Zhang R, Li W, Sun Q, Feng Z, Wu J. First Report of Pectobacterium punjabense Causing Blackleg and Soft Rot on Potato in Hebei and Fujian Province, China. PLANT DISEASE 2022; 106:PDIS12212731PDN. [PMID: 35029508 DOI: 10.1094/pdis-12-21-2731-pdn] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
|
179
|
Sun LH, Wu J, Wu J, Zhang ZK, Li WQ, Wang MY. [Design of wearable auxiliary device based on upper limb lifting workers and ergonomics simulation analysis]. ZHONGHUA LAO DONG WEI SHENG ZHI YE BING ZA ZHI = ZHONGHUA LAODONG WEISHENG ZHIYEBING ZAZHI = CHINESE JOURNAL OF INDUSTRIAL HYGIENE AND OCCUPATIONAL DISEASES 2022; 40:454-458. [PMID: 35785903 DOI: 10.3760/cma.j.cn121094-20200821-00485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
In order to solve the problem of high incidence of work-related musculoskeletal disorders (WMSDs) in upper limb lifting workers, a wearable auxiliary device which could be used in upper limb lifting operation was designed. The auxiliary device could be used in upper limb lifting through torsion spring device to reduce the tension of the arm muscles. The back bracket could be adjusted to adapt to the wearers of different height. The 3D model of the auxiliary device was constructed by using SoildWorks software. And the relative position and constraint between the auxiliary device and the digital simulation human were adjusted by using Jack as the main simulation tool. And then the virtual model of upper limb lifting were simulated and analyzed. Through the comparison of Rapid Upper Limb Assessment (RULA) scale, Krist comfort score and simulation results of two-handed reachable domain before and after wearing the auxiliary device, which proved that the wearable auxiliary device could reduce the risk of WMSDs in upper limb lifting workers.
Collapse
|
180
|
Hu XY, Wu J, Seal P, Ghaznavi SA, Symonds C, Kinnear S, Paschke R. Improvement in thyroid ultrasound report quality with radiologists' adherence to 2015 ATA or 2017 TIRADS: a population study. Eur Thyroid J 2022; 11:e220035. [PMID: 35521979 PMCID: PMC9254273 DOI: 10.1530/etj-22-0035] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Accepted: 05/05/2022] [Indexed: 11/08/2022] Open
Abstract
Objectives There has been slow adoption of thyroid ultrasound guidelines with adherence rates as low as 30% and no population-based studies investigating adherence to guideline-based malignancy risk assessment. We therefore evaluated the impact of adherence to the 2015 ATA guidelines or 2017 ACR-TIRADS guidelines on the quality of thyroid ultrasound reports in our healthcare region. Methods We reviewed 899 thyroid ultrasound reports of patients who received fine-needle aspiration biopsy and were diagnosed with Bethesda III or IV nodules or thyroid cancer. Ultrasounds were reported by radiology group 1, group 2, or other groups, and were divided into pre-2018 (before guideline adherence) or 2018 onwards. Reports were given a utility score (0-6) based on how many relevant nodule characteristics were included. Results Group 1 had a pre-2018 utility score of 3.62 and 39.4% classification reporting rate, improving to 5.77 and 97.0% among 2018-onwards reports. Group 2 had a pre-2018 score of 2.8 and reporting rate of 11.5%, improving to 5.58 and 93.3%. Other radiology groups had a pre-2018 score of 2.49 and reporting rate of 32.2%, improving to 3.28 and 61.8%. Groups 1 and 2 had significantly higher utility scores and reporting rates in their 2018-onward reports when compared to other groups' 2018-onward reports, pre-2018 group 1 reports, and pre-2018 group 2 reports. Conclusions Dedicated adherence to published thyroid ultrasound reporting guidelines can lead to improvements in report quality. This will reduce diagnostic ambiguity and improve clinician's decision-making, leading to overall reductions in unnecessary FNA biopsy and diagnostic surgery.
Collapse
|
181
|
Wu J, Huang Z, Huang W, Lv C. Prioritized Experience-Based Reinforcement Learning With Human Guidance for Autonomous Driving. IEEE TRANSACTIONS ON NEURAL NETWORKS AND LEARNING SYSTEMS 2022; PP:855-869. [PMID: 35687630 DOI: 10.1109/tnnls.2022.3177685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Reinforcement learning (RL) requires skillful definition and remarkable computational efforts to solve optimization and control problems, which could impair its prospect. Introducing human guidance into RL is a promising way to improve learning performance. In this article, a comprehensive human guidance-based RL framework is established. A novel prioritized experience replay mechanism that adapts to human guidance in the RL process is proposed to boost the efficiency and performance of the RL algorithm. To relieve the heavy workload on human participants, a behavior model is established based on an incremental online learning method to mimic human actions. We design two challenging autonomous driving tasks for evaluating the proposed algorithm. Experiments are conducted to access the training and testing performance and learning mechanism of the proposed algorithm. Comparative results against the state-of-the-art methods suggest the advantages of our algorithm in terms of learning efficiency, performance, and robustness.
Collapse
|
182
|
Wu J, Yu HH, Yu H, Gao B. [Digital rehabilitation of removable partial denture for a microstomic patient: a case report]. ZHONGHUA KOU QIANG YI XUE ZA ZHI = ZHONGHUA KOUQIANG YIXUE ZAZHI = CHINESE JOURNAL OF STOMATOLOGY 2022; 57:625-628. [PMID: 35692007 DOI: 10.3760/cma.j.cn112144-20211103-00483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
|
183
|
Larvin H, Kang J, Aggarwal VR, Pavitt S, Wu J. Systemic Multimorbidity Clusters in People with Periodontitis. J Dent Res 2022; 101:1335-1342. [PMID: 35678074 PMCID: PMC9516606 DOI: 10.1177/00220345221098910] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
This study aimed to identify systemic multimorbidity clusters in people with periodontitis via a novel artificial intelligence-based network analysis and to explore the effect of associated factors. This study utilized cross-sectional data of 3,736 participants across 3 cycles of the National Health and Nutrition Examination Survey (2009 to 2014). Periodontal examination was carried out by trained dentists for participants aged ≥30 y. The extent of periodontitis was represented by the proportion of sites with clinical attachment loss (CAL)≥ 3 mm, split into 4 equal quartiles. A range of systemic diseases reported during the survey were also extracted. Hypergraph network analysis with eigenvector centralities was applied to identify systemic multimorbidity clusters and single-disease influence in the overall population and when stratified by CAL quartile. Individual factors that could affect the systemic multimorbidity clusters were also explored by CAL quartile. In the study population, the top 3 prevalent diseases were hypertension (63.9%), arthritis (47.6%), and obesity (45.9%). A total of 106 unique systemic multimorbidity clusters were identified across the study population. Hypertension was the most centralized disease in the overall population (centrality [C]: 0.50), followed closely by arthritis (C: 0.45) and obesity (C: 0.42). Diabetes had higher centrality in the highest CAL quartile (C: 0.31) than the lowest (C: 0.26). "Hypertension, obesity" was the largest weighted multimorbidity cluster across CAL quartiles. This study has revealed a range of common systemic multimorbidity clusters in people with periodontitis. People with periodontitis are more likely to present with hypertension and obesity together, and diabetes is more influential to multimorbidity clusters in people with severe periodontitis. Factors such as ethnicity, deprivation, and smoking status may also influence the pattern of multimorbidity clusters.
Collapse
|
184
|
Vadhariya A, Birt J, Wu J, Griffing K, Bailey F, Hetherington J, Rottier E, Barlow S, Costenbader K. POS0743 CLINICAL CHARACTERISTICS AND BURDEN AMONG PATIENTS WITH SLE AND MUSCULOSKELETAL ORGAN INVOLVEMENT: RESULTS FROM A REAL-WORLD STUDY IN THE US. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundLimited information exists concerning the clinical burden and unmet need of musculoskeletal (MSK) organ involvement among patients with SLE in clinical practice.ObjectivesTo examine demographics, clinical status, treatment patterns, and patient-reported outcomes (PROs) among patients with SLE in clinical practices and assess the impact of MSK organ involvement.MethodsData were drawn from the Adelphi Real World Lupus IV (2021) Disease Specific Programme™, a point-in-time survey of 79 US physicians and their patients with SLE. Physicians completed questionnaires regarding patient demographics, clinical status, and treatment. The same patients were invited to complete questionnaires containing the EuroQoL 5-Dimensions (EQ-5D), Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue) and Work Productivity & Activity Impairment questionnaire (WPAI) PRO tools.Physicians stated their patients’ organ involvement at the time of data collection (current), in the categories of musculoskeletal, mucocutaneous, renal, cardiorespiratory, constitutional, haematologic, ophthalmologic, gastrointestinal, respiratory, or other.Two mutually exclusive patient groups were analysed:A.MSK – Current physician assessed musculoskeletal organ involvement (+/- other organ/tissue involvement).B.Non-MSK – No current musculoskeletal organ involvement as assessed by the physicianBivariate analysis was conducted for numeric variables using t-tests; binary categorical variables using a Fisher’s exact test; ordinal categorical variables using a Mann-Whitney test; and other categorical variables were compared using a chi-squared test.ResultsA total of 595 patients were included in this analysis: 64.7% MSK and 35.3% non-MSK. Mean[SD] patient age was 45.2[14.3] years, 83.2% were female, 53.3% were White/Caucasian, 27.9% were African American, and mean[SD] time diagnosed with any SLE was 5.3[6.2] years.Point-in-time assessment of clinical status, treatment patterns and patient-reported outcomes, revealed that those with MSK organ involvement assessed by their rheumatologist had higher overall SLE disease severity, more flares in the last 12 months, and slightly worse quality of life scores and work impairment.Table 1.Point-in-time clinical status, treatment patterns and PROs among patients with SLE MSK organ involvementTotalMSKNon-MSKp value(n=595)(n=385)(n=210)Physician-Reported Patient Clinical Status & Treatment HistoryCurrent SLE severity, n(%)Mild405 (68.1)243 (63.1)162 (77.1)<0.001Moderate169 (28.4)128 (33.3)41 (19.2)Severe21 (3.5)14 (3.6)7 (3.3)Current joint symptoms, n(%)Joint tenderness251 (42.2)210 (54.6)41 (19.5)<0.001Joint stiffness255 (42.9)212 (55.1)43 (20.5)<0.001Joint swelling135 (22.7)111 (28.8)24 (11.4)<0.001Mean [SD] Flares in the last 12 months1.6 [1.7]1.7 [1.8]1.2 [1.3]0.015Currently prescribed, n(%)Belimumab113 (19.0)79 (20.5)34 (16.2)0.198Immunosuppressant164 (27.6)105 (27.3)59 (28.1)0.830Corticosteroids333 (56.0)228 (59.2)105 (50.0)0.030Antimalarials429 (72.1)268 (69.6)161 (76.7))0.067Mean [SD] years on current treatment2.9 [3.6]2.5 [3.0]3.6 [4.4]<0.001Patient-Reported OutcomesMean [SD] EQ5D-5L Utility score (0= death to 1= full health)0.79 [0.20]0.76 [0.22]0.85 [0.16]0.002Mean [SD] FACIT-Fatigue score (0 worst fatigue to-52= no fatigue)32.4 [12.0]31.0 [11.5]35.4 [12.6]0.005Mean [SD] WPAI, overall work impairment score(0= no impact to 100= completely impacted)29.0 [21.0]30.5 [18.6]25.9 [25.2]0.223ConclusionIn this large sample of patients with SLE followed in clinical practices in the U.S., compared to those with little or no rheumatologist assessed MSK involvement, those with MSK involvement, had lower quality of life, with higher impact on their work productivity. These results highlight the heterogeneity of SLE and the impact of major MSK manifestations on quality of life in SLE.ReferencesN/ADisclosure of InterestsAisha Vadhariya Employee of: Eli Lilly and Company, Julie Birt Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jianmin Wu Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Kirstin Griffing Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Fiona Bailey: None declared, James Hetherington: None declared, Elke Rottier: None declared, Sophie Barlow: None declared, Karen Costenbader Consultant of: Lilly, Astra Zeneca, Janssen, Amgen, Glaxo Smith Kline, Grant/research support from: Exagen, Gilead, Merck
Collapse
|
185
|
Vadhariya A, Birt J, Wu J, Griffing K, Bailey F, Hetherington J, Rottier E, Barlow S, Costenbader K. AB0554 CLINICAL CHARACTERISTICS AND BURDEN AMONG PATIENTS WITH SLE STRATIFIED BY SLEDAI DERIVED SEVERITY: RESULTS FROM A REAL-WORLD STUDY IN THE US. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundData are limited concerning the distribution of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores among patients with SLE in clinical practice and the characteristics of patients with specific SLEDAI scores.ObjectivesTo investigate SLE patient demographics, clinical status, treatment patterns, and patient reported outcomes (PROs), overall and stratified by SLEDAI score.MethodsData were drawn from the Adelphi Real World Lupus IV (2021) Disease Specific Programme™, a point-in-time survey of 79 US rheumatologists and patients with SLE. Rheumatologists completed questionnaires regarding patient demographics, clinical status, and treatment. The same patients were invited to complete questionnaires containing the EuroQoL 5-Dimensions (EQ-5D), Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue) and Work Productivity & Activity Impairment questionnaire (WPAI) Patient-Reported Outcomes (PRO) tools.Physicians completed 24 questions based on the SLEDAI-2K questionnaire regarding their patients’ current clinical manifestations, from which a SLEDAI score was derived1. Patients were grouped based on their score: SLEDAI=0 (none), SLEDAI=1-6 (mild), SLEDAI=7-12 (moderate), and SLEDAI>12 (severe)2.Data from patients without rheumatologist-perceived renal organ involvement and ≥ 1 year of SLE duration were included for analysis using bivariate tests.ResultsA total of 273 patients were included in this analysis. Mean [SD] patient age was 47.0[14.2] years, 83.9% were female, 57.1% were White/Caucasian, and 24.9% were African American.Table 1.Point-in-time clinical status, treatment patterns and PROs among patients with SLE stratified by SLEDAI scoreTable 1.Total Sample (n=273)SLEDAI=0 (n=60, 22%)SLEDAI=1-6 (n=79, 28.9%)SLEDAI=7-12 (n=70, 25.6%)SLEDAI>12 (n=64, 23.4%)p valuePhysician-Reported Clinical Status and Treatment HistoryCurrent SLE severity, n(%)Mild221 (81.0)51 (85.0)70 (88.6)53 (75.7)47 (73.4)0.057Moderate49 (18.0)9 (15.0)9 (11.4)16 (22.9)15 (23.4)Severe3 (1.1)0 (0.0)0 (0.0)1 (1.4)2 (3.1)Current joint symptoms, n(%)Joint tenderness109 (39.9)24 (40.0)27 (34.2)28 (40.0)30 (46.9)0.498Joint stiffness121 (44.3)22 (36.7)33 (41.8)37 (52.9)29 (45.3)0.293Joint swelling60 (22.0)17 (28.3)13 (16.5)19 (27.1)11 (17.2)0.190Mean [SD] Flares in the last 12 months1.6 [1.5]1.3 [1.2]1.7 [1.7]1.5 [1.3]1.8 [1.5]0.550Currently prescribed, n(%)Belimumab58 (21.3)14 (23.3)18 (12.9)8 (10.1)15 (21.4)0.011Immunosuppressants48 (17.6)7 (11.7)26 (18.6)10 (12.7)13 (18.6)0.052Corticosteroids138 (50.6)35 (58.3)62 (44.3)29 (36.7)32 (45.7)0.003Antimalarials206 (75.5)28 (46.7)108 (77.1)64 (81.0)59 (84.3)<0.001Patient-Reported OutcomesMean [SD] EQ5D-5L Utility score (0=death to 1= full health)0.79 [0.19]0.83 [0.12]0.82 [0.21]0.79 [0.14]0.69 [0.25]0.024Mean [SD] FACIT-Fatigue score (0=worst fatigue to 52= no fatigue)32.7 [12.2]36.8 [8.7]36.1 [12.5]29.1 [9.8]26.4 [14.3]<0.001Mean [SD] WPAI overall (0= no impact to 100= completely impacted)26.8 [21.2]25.2 [15.8]19.5 [23.6]35.7 [20.2]31.9 [26.7]0.13149% of SLE patients were categorized as SLEDAI 7-12 or >12 (moderate or severe).Among the SLEDAI 7-12 (moderate) patients, 75.7% were subjectively categorized by their physician as having mild SLE. Of the SLEDAI >12 patients (severe), 73.4% were categorized as having mild SLE.Joints symptoms and flaring in the last 12 months were not significantly different across SLEDAI groups.Patients with greater SLEDAI reported lower EQ5D and greater FACIT-Fatigue scores. There was no statistical difference in WPAI between the SLEDAI groups.ConclusionA disconnect between point-in-time SLEDAI and physician-perceived severity exists. Patients with SLE, irrespective of SLEDAI, had high prevalence of joint symptoms, but higher SLEDAI impacted quality of life.References[1]Gladman D et al., Journal of Rheumatology, 2002.[2]Fanouriakis A et al., Annals of the rheumatic diseases, 2019.Disclosure of InterestsAisha Vadhariya Employee of: Eli Lilly and Company, Julie Birt Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jianmin Wu Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Kirstin Griffing Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Fiona Bailey: None declared, James Hetherington: None declared, Elke Rottier: None declared, Sophie Barlow: None declared, Karen Costenbader Consultant of: Lilly, Astra Zeneca, Janssen, Amgen, Glaxo Smith Kline, Grant/research support from: Exagen, Gilead, Merck
Collapse
|
186
|
Ren Z, Li Z, Zhang T, Fang W, Hu S, Pan H, Yen C, Hou J, Chen Y, Shao G, Hsu C, Bai Y, Meng Z, Hou M, Xie C, Liu Y, Wu J, Li B, Chica-Duque S, Cheng A. P-25 Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
187
|
Yin MG, Wang XT, Liu DW, Chao YG, Kang Y, He W, Zhang HM, Wu J, Liu LX, Zhu R, Zhang LN. [The quality control standards and principles of the application and training of critical ultrasonography]. ZHONGHUA NEI KE ZA ZHI 2022; 61:631-643. [PMID: 35673743 DOI: 10.3760/cma.j.cn112138-20220111-00031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Critical ultrasonography is widely used in ICU and has become an indispensable tool for clinicians. However, besides operator-dependency of critical ultrasonography, lack of standardized training mainly result in the physicians' heterogenous ultrasonic skill. Therefore, standardized training as well as strict quality control plays the key role in the development of critical ultrasonography. We present this quality control standards to promote better development of critical ultrasonography.
Collapse
|
188
|
Zheng X, Chen Z, Wu X, LI X, Xie Y, Wu J, Xiao M, Cao S, Wei Q, Zhu W, Rao Y, Chen Q, Wen Y, Gu J. POS1002 DIAGNOSTIC DELAY AND ITS ASSOCIATED FACTORS IN CHINESE AXIAL SPONDYLOARTHRITIS: A RETROSPECTIVE STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundFew data on the prolonged diagnosis and its associated factors in Chinese axial spondyloarthritis (axSpA) is available.ObjectivesTo delineate the landscape of diagnostic delay in Chinese axSpA, investigate its associated factors and explore its potential impact on medication modalities.MethodsA total of 1,295 patients fulfilling the ASAS classification criteria were obtained. Demographic and clinical data were collected through predesigned questionnaires and available medical records. Logistic regression analyses in univariate and multivariable model were performed, using the median of diagnostic delay as cut-off point for group classification. Differences between early and late diagnosed group were subsequently compared by the Pearson chi-square test or Mann-Whitney U test.ResultsThe median (IQR) diagnostic delay in Chinese axSpA was 3.0 (1.0~7.0) years and 24.8% of them reported a history of misdiagnosis. Older age at onset (OR=0.97, P<0.001) and higher education attainment (P=0.001) were correlated with early diagnosis of axSpA, whereas coming from less developed areas (P=0.002), a history of peripheral arthritis at the time of diagnosis (OR=1.58, P=0.002) and history of misdiagnosis (OR=1.98, P<0.001) increased the risk of diagnostic delay. Medication modalities were similar between two groups, but the proportion with no medication ever and percentage without regular medication in recent 3 months were higher in the late diagnosed group than early group (26.5% vs. 20.7%, P=0.02; 34.7% vs. 28.6%, P=0.02).ConclusionOur findings depicted a detailed spectrum of diagnostic delay in Chinese axSpA, verified five associated factors and pinpointed a remarkable treatment delay even after diagnosis, especially in late diagnosis group.References[1]Masson Behar V, Dougados M, Etcheto A, Kreis S, Fabre S, Hudry C, et al. Diagnostic delay in axial spondyloarthritis: A cross-sectional study of 432 patients. Joint bone spine. 2017;84(4):467-71.Figure 1.Cumulative distribution of age at onset and age at diagnosis in Chinese axSpA(A) the entire group. (B) stratified by early and late diagnosed group. (C) stratified by education level (college, middle school, secondary school). (D) stratified by history of peripheral arthritis when diagnosed. (E) stratified by history of misdiagnoses when diagnosed. (F) stratified by native place, as statistical significance was found between eastern coastal and western China, only these two groups were presented.Disclosure of InterestsNone declared
Collapse
|
189
|
Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. POS0674 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundORAL Surveillance (NCT02092467) was a post-approval safety study of tofacitinib vs TNF inhibitors (TNFi) in rheumatoid arthritis (RA) patients (pts) aged ≥50 yrs with ≥1 additional cardiovascular (CV) risk factor and an inadequate response to methotrexate (MTX).ObjectivesTo identify independent risk factors for major adverse CV events (MACE) in ORAL Surveillance.MethodsPts on stable MTX were randomised 1:1:1 to receive tofacitinib 5 or 10 mg twice daily (BID) or a TNFi (adalimumab 40 mg every 2 weeks or etanercept 50 mg once weekly). Incidence rates (IRs; pts with first events/100 pt-yrs) and hazard ratios (HRs; tofacitinib vs TNFi) were assessed for adjudicated MACE (total/fatal/non-fatal), sudden cardiac death, and total/fatal/non-fatal myocardial infarction (MI) and stroke. Post hoc univariate Cox model analyses identified potentially independent baseline (BL) risk factors for MACE across treatments; those with p<0.10 were entered into a multivariate Cox model using backward selection (p<0.10 stay criteria). MACE HRs were produced for subgroups for BL risk factors with p<0.05 in the final multivariate Cox model.Results4362 pts were included (tofacitinib 5 mg BID, n=1455; tofacitinib 10 mg BID, n=1456; TNFi, n=1451). IRs for total/fatal/non-fatal MACE, sudden cardiac death, and total/non-fatal MI were higher with tofacitinib vs TNFi (Table 1). Fatal MI and stroke (including fatal/non-fatal events) IRs were similar across treatments (Table 1). Total MACE and MI IRs and risk were higher with tofacitinib vs TNFi (HRs >1) and higher for non-fatal MI for tofacitinib 5 mg BID (Table 1). Current smoking, aspirin use, history of chronic lung disease, history of diabetes, male sex and older age were BL risk factors for MACE. While MACE risk was generally higher with tofacitinib vs TNFi across all BL risk factors, increased risk was clearest in current/past smokers (vs never smoked) and aspirin users (vs non-users) (Figure 1). When age and smoking status were considered in combination, pts aged ≥65 yrs or who had ever smoked had a particularly elevated MACE risk vs never smokers aged ≥50–<65 yrs (Figure 1).Table 1.MACE, MI and stroke IRs (pts with first events/100 pt-yrs; 95% CI) and HRs (tofacitinib vs TNFi; 95% CI)Tofacitinib 5 mg BID(N=1455)Tofacitinib 10 mg BID(N=1456)TNFi(N=1451)nIRHRnIRHRnIR(95% CI)(95% CI)(95% CI)(95% CI)(95% CI)MACE470.911.24511.051.43370.73(0.67, 1.21)(0.81, 1.91)(0.78, 1.38)(0.94, 2.18)(0.52, 1.01)Fatal MACE140.271.14190.391.63120.24(0.15, 0.45)(0.53, 2.47)(0.23, 0.60)(0.79, 3.36)(0.12, 0.41)Non-fatal MACE330.641.29320.661.33250.50(0.44, 0.90)(0.77, 2.17)(0.45, 0.93)(0.79, 2.24)(0.32, 0.73)Sudden cardiac death100.191.22130.261.6780.16(0.09, 0.35)(0.48, 3.10)(0.14, 0.45)(0.69, 4.04)(0.07, 0.31)MI190.371.69190.391.80110.22(0.22, 0.57)(0.80, 3.55)(0.23, 0.61)(0.85, 3.77)(0.11, 0.39)Fatal MI00NI30.061.0330.06(0.00, 0.07)(0.01, 0.18)(0.21, 5.11)(0.01, 0.17)Non-fatal MI190.372.32160.332.0880.16(0.22, 0.57)(1.02, 5.30)a(0.19, 0.53)(0.89, 4.86)(0.07, 0.31)Stroke180.351.03180.371.10170.34(0.21, 0.55)(0.53, 2.00)(0.22, 0.58)(0.57, 2.13)(0.20, 0.54)Fatal stroke40.08NI20.04NI00.00(0.02, 0.20)(0.00, 0.15)(0.00, 0.07)Non-fatal stroke140.270.80160.330.97170.34(0.15, 0.45)(0.40, 1.63)(0.19, 0.53)(0.49, 1.93)(0.20, 0.54)aHR 95% CI excludes 1.Data collected after pts who were randomised to tofacitinib 10 mg BID had their dose reduced to 5 mg. BID were included in the tofacitinib 10 mg BID group. HRs (95% CI) were not informative when one of the treatments in the comparison had 0 events.Risk period was defined as time from first dose to last dose +60 days or to the last contact date, whichever was earlier.CI, confidence interval; NI, non-informativeConclusionMACE IRs and risk were higher with tofacitinib vs TNFi in ORAL Surveillance. BL risk factor findings could aid identification of RA pts with potentially highest risk for MACE, with a view to informing treatment decisions.AcknowledgementsStudy sponsored by Pfizer Inc. Medical writing support was provided by Kirsten Woollcott, CMC Connect, and funded by Pfizer Inc.Disclosure of InterestsChristina Charles-Schoeman Consultant of: AbbVie, Gilead Sciences, Pfizer Inc and Sanofi-Regeneron, Grant/research support from: AbbVie, Bristol-Myers Squibb and Pfizer Inc, Maya H Buch Speakers bureau: AbbVie, Consultant of: AbbVie, Eli Lilly, Gilead Sciences, MSD, Pfizer Inc and Roche, Grant/research support from: Pfizer Inc, Roche and UCB, Maxime Dougados Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB, Deepak L Bhatt Grant/research support from: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eli Lilly, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Medtronic, MyoKardia, Novo Nordisk, Owkin, Pfizer Inc, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic and The Medicines Company, Jon T Giles Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Genentech, Gilead Sciences and UCB, Grant/research support from: Pfizer Inc, Steven R. Ytterberg Consultant of: Corbus Pharmaceuticals, Kezar Life Sciences and Pfizer Inc, Gary G Koch Shareholder of: IQVIA, Grant/research support from: AbbVie, Acceleron, Amgen, Arena, AstraZeneca, Cytokinetics, Eli Lilly, Gilead, GSK, Huya Bioscience International, Johnson & Johnson, Landos Biopharma, Merck, Momentum, Novartis, Otsuka, Pfizer Inc, Sanofi and vTv Therapeutics, Employee of: University of North Carolina at Chapel Hill, Ivana Vranic Shareholder of: Pfizer Inc, Employee of: Pfizer Ltd, Joseph Wu Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Cunshan Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Sujatha Menon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Jose L. Rivas Shareholder of: Pfizer Inc, Employee of: Pfizer SLU, Arne Yndestad Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Carol A. Connell Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Zoltán Szekanecz Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche and Sanofi, Paid instructor for: AbbVie, Eli Lilly, Gedeon Richter, Novartis, Pfizer Inc and Roche, Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche and Sanofi
Collapse
|
190
|
Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH. OP0264 IMPACT OF BASELINE CARDIOVASCULAR RISK ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS CLINICAL PROGRAMME. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundResults from ORAL Surveillance, a post-authorisation safety study, indicated that patients (pts) with rheumatoid arthritis (RA) aged ≥50 yrs with ≥1 additional cardiovascular (CV) risk factor have an increased risk of major adverse CV events (MACE) with tofacitinib vs tumour necrosis factor inhibitors.1ObjectivesTo evaluate the impact of baseline (BL) CV risk on MACE in the wider tofacitinib RA clinical programme.MethodsData for pts who received ≥1 tofacitinib dose in 21 Phase 1–3b/4 (excluding ORAL Surveillance) and 2 long-term extension tofacitinib RA studies were pooled and analysed post hoc as two cohorts: (1) overall cohort and (2) CV risk-enriched cohort (pts aged ≥50 yrs with ≥1 additional CV risk factor [current smoker, hypertension, HDL-cholesterol <40 mg/dL, diabetes mellitus, history of myocardial infarction (MI) or coronary heart disease (CHD)]). Data were summarised by average tofacitinib 5 or 10 mg twice daily (BID; average total daily dose of <15 or ≥15 mg, respectively). Incidence rates (IRs; pts with first events/100 pt-yrs) for adjudicated MACE were calculated. MACE IRs were stratified by pts’ BL CV risk profile: pts were first categorised by history of coronary artery disease (HxCAD), then pts without a HxCAD were categorised by 10-yr risk of MACE, per the ASCVD-PCE risk calculator2 with a 1.5 multiplier applied.3ResultsThe overall cohort included 7964 pts (average tofacitinib 5 mg BID, n=3969; average tofacitinib 10 mg BID, n=3995); of these, 3125 (39.2%) pts were included in the CV risk-enriched cohort (average tofacitinib 5 mg BID, n=1614; average tofacitinib 10 mg BID, n=1511). In both treatment arms, as expected, higher proportions of pts in the CV risk-enriched cohort had a HxCAD or a high or intermediate 10-yr predicted risk of MACE at BL vs the overall cohort (Table 1). MACE IRs (95% CIs) were lower in the overall cohort (0.38 [0.26, 0.54] and 0.37 [0.27, 0.48] for average tofacitinib 5 and 10 mg BID, respectively) vs the CV risk-enriched cohort (0.72 [0.46, 1.09] and 0.67 [0.46, 0.93], respectively), and were similar between treatment arms. MACE IRs were lower than reported in ORAL Surveillance.1 In the overall cohort, adjudicated MACE most commonly occurred in pts with a HxCAD (IR [95% CI] 0.98 [0.02, 5.47] and 1.05 [0.13, 3.78] for average tofacitinib 5 and 10 mg BID, respectively), or in pts with a high 10-yr risk of MACE at BL (Figure 1). A lower predicted 10-yr MACE risk was associated with lower MACE IRs (Figure 1); trends were similar for the CV risk-enriched cohort (data not shown).Table 1.Proportions of pts with a HxCAD and pts without a HxCAD categorised by 10-yr risk of MACE, per ASCVD-PCE risk calculator2 with a 1.5 multiplier applied3Average tofacitinib 5 mg BIDAverage tofacitinib 10 mg BIDOverall cohort(N=3969)CV risk-enriched cohort(N=1614)Overall cohort(N=3995)CV risk-enriched cohort(N=1511)HxCAD, n (%)61 (1.5)61 (3.8)65 (1.6)60 (4.0)No HxCAD: 10-yr risk of MACE, n (%)High (≥20%)440 (11.1)365 (22.6)337 (8.4)276 (18.3)Intermediate (≥7.5–<20%)853 (21.5)593 (36.7)788 (19.7)530 (35.1)Borderline (≥5–<7.5%)435 (11.0)234 (14.5)404 (10.1)195 (12.9)Low (<5%)2133 (53.7)342 (21.2)2058 (51.5)307 (20.3)Missing data47 (1.2)19 (1.2)343 (8.6)143 (9.5)CAD is defined as any of MI or CHD.n, number of pts with specified characteristic; N, number of evaluable ptsConclusionIn the tofacitinib RA clinical programme, MACE were largely associated with BL CV risk in the overall cohort, consistent with results of ORAL Surveillance, although results should be interpreted with caution due to low pt-yrs of exposure in some pt groups. Noting this limitation, these findings emphasise the importance of assessing and addressing BL CV risk when treating pts with RA.References[1]Ytterberg et al. New Engl J Med 2022; 386: 316-326.[2]American College of Cardiology, American Heart Association. ASCVD risk estimator. https://tools.acc.org/ldl/ascvd_risk_estimator/index.html#!/calulate/estimator/.[3]Agca et al. Ann Rheum Dis 2017; 76: 17-28.AcknowledgementsStudy sponsored by Pfizer Inc. Medical writing support was provided by Kirsten Woollcott, CMC Connect, and funded by Pfizer Inc.Disclosure of InterestsMaxime Dougados Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB, Christina Charles-Schoeman Consultant of: AbbVie, Gilead Sciences, Pfizer Inc and Sanofi-Regeneron, Grant/research support from: AbbVie, Bristol-Myers Squibb and Pfizer Inc, Zoltán Szekanecz Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche and Sanofi, Paid instructor for: AbbVie, Eli Lilly, Gedeon Richter, Novartis, Pfizer Inc and Roche, Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche and Sanofi, Grant/research support from: Pfizer Inc, Jon T Giles Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Genentech, Gilead Sciences and UCB, Grant/research support from: Pfizer Inc, Steven R. Ytterberg Consultant of: Corbus Pharmaceuticals, Kezar Life Sciences and Pfizer Inc, Deepak L Bhatt Grant/research support from: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Eli Lilly, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Medtronic, MyoKardia, Novo Nordisk, Owkin, Pfizer Inc, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic and The Medicines Company, Gary G Koch Grant/research support from: AbbVie, Acceleron, Amgen, Arena, AstraZeneca, Cytokinetics, Eli Lilly, Gilead Sciences, GSK, Huya Bioscience International, Johnson & Johnson, Landos Biopharma, Merck, Momentum, Novartis, Otsuka, Pfizer Inc, Sanofi and vTv Therapeutics, Employee of: University of North Carolina at Chapel Hill, Ivana Vranic Shareholder of: Pfizer Inc, Employee of: Pfizer Ltd, Joseph Wu Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Cunshan Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Kenneth Kwok Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Sujatha Menon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Carol A. Connell Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Arne Yndestad Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Jose L. Rivas Shareholder of: Pfizer Inc, Employee of: Pfizer SLU, Maya H Buch Speakers bureau: AbbVie, Consultant of: AbbVie, Eli Lilly, Gilead Sciences, MSD, Pfizer Inc and Roche, Grant/research support from: Pfizer Inc, Roche and UCB
Collapse
|
191
|
Giles JT, Charles-Schoeman C, Buch MH, Dougados M, Szekanecz Z, Ytterberg SR, Koch GG, Wu J, Wang C, Kwok K, Menon S, Chen Y, Cesur TY, Rivas JL, Yndestad A, Diehl A, Bhatt DL. POS0520 ASSOCIATION BETWEEN BASELINE STATIN TREATMENT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundORAL Surveillance (NCT02092467) was a post-authorisation safety study of tofacitinib vs tumour necrosis factor inhibitors (TNFi) in patients (pts) with rheumatoid arthritis (RA) aged ≥50 years (yrs) with ≥1 additional cardiovascular (CV) risk factor and an inadequate response to methotrexate (MTX). Statins are used to treat coronary artery disease (CAD) and are recommended by the American College of Cardiology/American Heart Association (ACC/AHA) for the management of pts at risk of atherosclerotic CV disease (ASCVD),1 such as those with ≥7.5% 10-yr risk of major adverse CV events (MACE) or diabetes mellitus.ObjectivesTo examine the association between baseline (BL) statin use and MACE in ORAL Surveillance.MethodsPts with RA on stable MTX were randomised 1:1:1 to receive tofacitinib 5 or 10 mg twice daily (BID) or TNFi (adalimumab 40 mg every 2 weeks or etanercept 50 mg once weekly). Pts were stratified post hoc by BL statin use (yes/no). Pts were further categorised by history of CAD (HxCAD), BL CV risk score per ACC/AHA guidelines1 (for pts without HxCAD; 10-yr risk of MACE per the ASCVD-pooled cohort equations risk calculator2 with a 1.5 multiplier applied3), and separately by BL diabetes status. CV risk score/BL diabetes status categories were: high (≥20%)/HxCAD (yes), intermediate (≥7.5–<20%) or low-borderline (<7.5%), and diabetes status (yes). For the overall population and each treatment group, risk of MACE was compared between BL statin use (yes vs no) via Cox analyses for each CV risk category and diabetes status (yes). Incidence rates (IRs; pts with first events/100 pt-yrs) and hazard ratios (HRs; BL statin use: yes vs no) were evaluated for adjudicated MACE.ResultsOf 4362 pts (tofacitinib 5 mg BID, n=1455; tofacitinib 10 mg BID, n=1456; TNFi, n=1451), 497 had a HxCAD, and 3813 without a HxCAD had CV risk scores determined; 789 had BL diabetes. Overall, 1020 (23.4%) pts reported BL statin use. Across CV risk score categories for all treatment groups, <50% of pts received statins at BL, with statin use highest in the high/HxCAD category pts (35.7–40.6%) and pts with diabetes (35.7–44.2%) (Table 1). Across categories, no interpretable associations between BL statin use and MACE were found. However, in the overall population, MACE IRs were lower in pts with vs without BL statin use in the high/HxCAD category, and in pts with diabetes (Figure 1). In pts receiving tofacitinib 5 mg BID and TNFi, MACE IRs were lower in pts with vs without BL statin use across all categories (Figure 1).Table 1.Proportion of pts receiving statins at BL, by CV risk category and presence of diabetesn/N (%)OverallTofacitinibTofacitinibTNFi5 mg BID10 mg BIDHigh (≥20%)/HxCAD525/1370 (38.3)168/435 (38.6)193/475 (40.6)164/460 (35.7)Intermediate (≥7.5–<20%)302/1511 (20.0)110/490 (22.4)94/516 (18.2)98/505 (19.4)Low-borderline (<7.5%)178/1429 (12.5)66/513 (12.9)57/446 (12.8)55/470 (11.7)Diabetes (yes)320/789 (40.6)111/251 (44.2)114/272 (41.9)95/266 (35.7)N, number of pts in each category; n, number of pts receiving BL statinsConclusionIn this post hoc analysis of data from ORAL Surveillance, most pts did not receive BL statin treatment. This suggests suboptimal CV risk management, particularly in pts at high risk of CV events. There was no interpretable association between BL statin use and MACE. However, pts in the higher risk categories, particularly those receiving tofacitinib 5 mg BID, had lower MACE IRs with vs without BL statin use. This analysis did not take into account initiation or dose adjustment of statin treatment during the study, and had low yrs of exposure in some categories.References[1]Arnett et al. J Am Coll Cardiol 2019; 74: e177-232.[2]American College of Cardiology, American Heart Association. ASCVD risk estimator. https://tools.acc.org/ldl/ascvd_risk_estimator/index.html#!/calulate/estimator/.[3]Agca et al. Ann Rheum Dis 2017; 76: 17-28.AcknowledgementsStudy sponsored by Pfizer Inc. Medical writing support was provided by Lauren Hogarth, CMC Connect, and funded by Pfizer Inc.Disclosure of InterestsJon T Giles Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Genentech, Gilead Sciences and UCB, Grant/research support from: Pfizer Inc, Christina Charles-Schoeman Consultant of: AbbVie, Gilead Sciences, Pfizer Inc and Sanofi-Regeneron, Grant/research support from: AbbVie, Bristol-Myers Squibb and Pfizer Inc, Maya H Buch Speakers bureau: AbbVie, Consultant of: AbbVie, Eli Lilly, Gilead Sciences, MSD, Pfizer Inc and Roche, Grant/research support from: Pfizer Inc, Roche and UCB, Maxime Dougados Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer Inc, Roche and UCB, Zoltán Szekanecz Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche and Sanofi, Paid instructor for: AbbVie, Eli Lilly, Gedeon Richter, Novartis, Pfizer Inc and Roche, Consultant of: AbbVie, Eli Lily, Novartis, Pfizer Inc, Roche and Sanofi, Steven R. Ytterberg Consultant of: Corbus Pharmaceuticals, Kezar Life Sciences and Pfizer Inc, Gary G Koch Shareholder of: IQVIA, Grant/research support from: AbbVie, Acceleron, Amgen, Arena, AstraZeneca, Cytokinetics, Eli Lilly, Gilead Scienes, GlaxoSmithKline, Huya Bioscience International, Johnson & Johnson, Landos Biopharma, Merck, Momentum, Novartis, Otsuka, Pfizer Inc, Sanofi and vTv Therapeutics, Employee of: University of North Carolina at Chapel Hill, Joseph Wu Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Cunshan Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Kenneth Kwok Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Sujatha Menon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Yan Chen Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Teoman Yusuf Cesur Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Jose L. Rivas Shareholder of: Pfizer Inc, Employee of: Pfizer SLU, Arne Yndestad Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Annette Diehl Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Deepak L Bhatt Grant/research support from: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, Novo Nordisk, Owkin, Pfizer Inc, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic and The Medicines Company.
Collapse
|
192
|
Alroobaea R, Rubaiee S, Hanbazazah AS, Jahrami H, Garbarino S, Damiani G, Wu J, Bragazzi NL. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2022; 26:4074-4081. [PMID: 35731078 DOI: 10.26355/eurrev_202206_28977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
OBJECTIVE Atopic dermatitis displays a relevant sleep burden sustained by clinical (i.e., itch), psychological (i.e., inadequate coping strategies) and therapeutic (i.e., frequent loss of drug response) triggers. Dupilumab, the first biologic approved for atopic dermatitis, showed excellent effects on improving pruritus and sleep after only two weeks of treatment but, in some cases, may have paradoxical effects. The rate of sleep-related side-effects remains unknown. More specifically, adverse-drug reactions (ADRs) related to dupilumab have been investigated during the safety phase of randomized clinical trials or in small retrospective epidemiological surveys, but little is known about sleep-related ADRs in real-life settings. Therefore, we took advantage of a global large-scale pharmacovigilance database, carrying out a comprehensive data mining analysis to look at different sleep-related ADRs reported among patients under anti IL-4/13 therapy. MATERIALS AND METHODS We analyzed individual case study reports (ICSRs) in VigiBaseTM, the World Health Organization (WHO) global pharmacovigilance database of ADRs collected by national drug authorities in > 140 countries (> 90% of the world population). We looked for patterns of potentially sleep-related ADRs and we applied a disproportionality analysis based on Bayesian Confidence Propagation Neural Network (BCPNN). A meta-analytical approach was used to synthesize the overall effect size of sleep-related ADRs potentially associated to Dupilumab administration. RESULTS From inception up to March 9, 2021, 94,065 ADRs from 37,848 unique reports were included and analyzed in the present paper: 1,294 of them (1.4%) concerned sleep disturbances (n=27). Most of sleep-related complaints were generic sleep disorders (n=630), followed by insomnia (n=312), somnolence (n=81), lethargy (n=60), night sweats (n=30), middle insomnia (n=39), hypersomnia (n=25), poor-quality sleep (n=21), initial insomnia (n=17), sleep apnea syndrome (n=13), nightmares (n=11) and sleep deficit (n=11). Interestingly, restlessness and restless leg syndrome, nocturnal dyspnea, narcolepsy and bruxism were reported in 7, 6, 5, 4 and 3 cases, respectively. Only sleep deficit [OR 15.67 (95% CrI 8.61-28.51); IC 3.24 (95% CrI 2.26-3.97)], generic sleep disorder [OR 6.22 (95% CrI 5.74-6.73); IC 2.60 (95% CrI 2.48-2.71)], nocturnal dyspnea [OR 3.68 (95% CrI 1.53-8.87); IC 1.56 (95% CrI 0.03-2.56)] and middle insomnia [OR 1.87 (95% CrI 1.36-2.56); IC 0.88 (95% CrI 0.39-1.30)] achieved the statistical significance threshold. CONCLUSIONS In this work, we identified over 37,000 unique case-reports of Dupilumab side-effects reported on the WHO pharmacovigilance database. We specifically categorized those related to sleep issues, which were 1,294. Our findings from large numbers of cases provide data supporting the clinical observations that Dupilumab is usually effective in improving sleep quality and sleep disturbances/impairments, given the lack of statistical significance of several sleep-related ADRs. Further work is needed to closely scrutinize the impact of Dupilumab on sleep, in terms of underlying mechanisms, and to better understand residual sleep disorders in patients with atopic dermatitis and other allergic diseases treated with Dupilumab. Thus, sleep monitoring may be helpful for dermatologists in managing atopic dermatitis patients treated with dupilumab. The limitations of spontaneous reporting systems including underreporting and reporting bias, heterogeneity of sources and impossibility to infer any causal relationship merit consideration and further research is needed.
Collapse
|
193
|
Deodhar A, Akar S, Curtis J, Zorkany B, Magrey M, Wang C, Wu J, Makgoeng SB, Vranic I, Menon S, Fleishaker D, Diehl A, Fallon L, Yndestad A, Landewé RBM. POS0296 INTEGRATED SAFETY ANALYSIS OF TOFACITINIB IN ANKYLOSING SPONDYLITIS CLINICAL TRIALS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundTofacitinib is an oral JAK inhibitor for the treatment of adults with ankylosing spondylitis (AS).ObjectivesTo describe the tofacitinib safety profile from an integrated analysis of randomised controlled trials (RCTs) in patients (pts) with active AS.MethodsPooled data from Phase (P)2 (NCT01786668) and P3 (NCT03502616) RCTs in pts with AS were analysed in 3 cohorts (Table 1): the 16-Week (Wk) placebo (PBO)-controlled cohort (pts receiving tofacitinib 5 mg twice daily [BID] or PBO from Wks 0–12 [P2 RCT] or Wks 0–16 [P3 RCT]), the 48-Wk all tofacitinib 5 mg BID cohort and the 48-Wk all tofacitinib cohort (pts receiving ≥1 dose of tofacitinib 2, 5 or 10 mg BID), including pts receiving tofacitinib from Wks 0–12 (P2 RCT) or Wks 0–48 (P3 RCT). Pts receiving tofacitinib 5 mg BID were included in the 16-Wk PBO-controlled cohort and both 48-Wk tofacitinib cohorts. Adverse event (AE)/AEs of special interest incidence rates (IRs; pts with events/100 pt-yrs) were reported based on a 28-day risk period (time of first to last study drug dose +28 days). Baseline (BL) cardiovascular (CV) risk was calculated post hoc by the atherosclerotic CV disease (ASCVD)-pooled cohort equations calculator for pts without history of coronary artery disease (48-Wk tofacitinib cohorts).ResultsAt BL, most pts (>76%) in the 48-Wk tofacitinib cohorts had <5% (low) 10-yr ASCVD risk (Figure 1). The most common treatment-emergent AEs were nasopharyngitis/upper respiratory tract infection. Serious AE IRs were higher with tofacitinib 5 mg BID vs PBO in the 16-Wk PBO-controlled cohort, and similar in the 48-Wk tofacitinib cohorts (Table 1). Discontinuation due to AEs was similar between groups in the 16-Wk PBO-controlled cohort and between the 48-Wk tofacitinib cohorts (Table 1). One pt receiving tofacitinib 5 mg BID (included in the 16-Wk PBO-controlled and both 48-Wk tofacitinib cohorts) had a serious infection (SI; meningitis; Table 1). No SIs with PBO. Herpes zoster (HZ; all non-serious) occurred in the 48-Wk all tofacitinib 5 mg BID (5 pts [1.6%]) and 48-Wk all tofacitinib cohorts (7 pts [1.7%]; Table 1) only. Most cases involved a single dermatome, but 1 pt (tofacitinib 10 mg BID) had HZ involving 2 adjacent dermatomes. Across cohorts, there were no deaths or adjudicated opportunistic infections (OIs), OIs excluding tuberculosis (TB), TB, malignancies excluding non-melanoma skin cancer (NMSC), NMSC, major adverse CV events, thromboembolic events, gastrointestinal perforation or interstitial lung disease. Uveitis was reported in 1 (0.5%), 3 (1.6%), 4 (1.3%) and 6 (1.4%) pts in the tofacitinib 5 mg BID, PBO, 48-Wk all tofacitinib 5 mg BID and 48-Wk all tofacitinib groups, respectively; all but 1 pt (tofacitinib 2 mg BID) had history of uveitis. Psoriasis occurred in 1 (0.5%) pt (PBO) with history of psoriasis. There were no AEs of inflammatory bowel disease.Table 1.AEs and AEs of special interest16-Wk PBO-controlled cohort48-Wk tofacitinib cohortsTofacitinib 5 mg BID N=185PBO N=18748-Wk all tofacitinib 5 mg BID N=31648-Wk all tofacitinib N=420AE, n (%), IR [95% CI per 100 pt-yrs]Serious AE3 (1.6) 5.28 [0.00, 11.25]2 (1.1) 3.56 [0.00, 8.49]8 (2.5) 3.49 [1.51, 6.87]9 (2.1) 3.45 [1.58, 6.55]Discontinuation due to AEs4 (2.2) 7.04 [0.14, 13.94]4 (2.1) 7.10 [0.14, 14.05]11 (3.5) 4.77 [2.38, 8.54]12 (2.9) 4.58 [2.37, 8.00]SI1 (0.5) 1.77 [0.00, 5.89]0 0.00 [0.00, 3.31]1 (0.3) 0.43 [0.01, 2.41]1 (0.2) 0.38 [0.01, 2.12]HZ0 0.00 [0.00, 3.28]0 0.00 [0.00, 3.31]5 (1.6) 2.18 [0.71, 5.08]7 (1.7) 2.68 [1.08, 5.53]All-cause mortality0 0.00 [0.00, 3.28]0 0.00 [0.00, 3.31]0 0.00 [0.00, 1.59]0 0.00 [0.00, 1.40]Malignancies excluding NMSC0 0.00 [0.00, 3.28]0 0.00 [0.00, 3.31]0 0.00 [0.00, 1.59]0 0.00 [0.00, 1.40]Major adverse CV event0 0.00 [0.00, 3.28]0 0.00 [0.00, 3.31]0 0.00 [0.00, 1.59]0 0.00 [0.00, 1.40]Venous thromboembolism0 0.00 [0.00, 3.28]0 0.00 [0.00, 3.31]0 0.00 [0.00, 1.59]0 0.00 [0.00, 1.40]CI, confidence interval; n, number of pts with event within 28-day risk periodConclusionTofacitinib 5 mg BID was well tolerated over 48 Wks in pts with AS, and safety was consistent with the established safety profile of tofacitinib.AcknowledgementsStudy sponsored by Pfizer Inc. Medical writing support was provided by Jennifer Arnold, CMC Connect, and funded by Pfizer Inc.Disclosure of InterestsAtul Deodhar Consultant of: AbbVie, Amgen, Aurinia, Boehringer Ingelheim, Bristol-Myers Squibb, Celegene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer Inc and UCB, Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer Inc and UCB, Servet Akar Speakers bureau: AbbVie, Amgen, Eli Lilly, MSD, Novartis, Pfizer Inc and UCB, Consultant of: AbbVie, Amgen, Eli Lilly, MSD, Novartis, Pfizer Inc and UCB, Grant/research support from: Pfizer Inc, Jeffrey Curtis Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, Roche and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, Roche and UCB, Bassel Zorkany Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eva, Eli Lilly, Hekma, Janssen, MSD, New Bridge, Novartis, Pfizer Inc, Roche, Sanofi-Aventis and Servier, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Eva, Eli Lilly, Hekma, Janssen, MSD, New Bridge, Novartis, Pfizer Inc, Roche, Sanofi-Aventis and Servier, Marina Magrey Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer Inc and UCB, Grant/research support from: AbbVie and UCB, Cunshan Wang Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Joseph Wu Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Solomon B Makgoeng Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Ivana Vranic Shareholder of: Pfizer Inc, Employee of: Pfizer Ltd, Sujatha Menon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Dona Fleishaker Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Annette Diehl Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Lara Fallon Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Arne Yndestad Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Robert B.M. Landewé Consultant of: AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Galapagos NV, Novartis, Pfizer Inc and UCB
Collapse
|
194
|
Wang Y, Shi T, Deng J, Wu J, Qu Y, Zhang Y, Zhu X, Liang B, Yu Q, Du H, Jie L. AB0390 COST-EFFECTIVENESS OF IGURATIMOD IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) BY USING A CLAIMS-BASED ALGORITHM: RETROSPECTIVE ANALYSIS OF REAL‑WORLD DATA. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundIguratimod (IGU), as one of the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), has been approved by National Medical Products Administration (NMPA) to treat Rheumatoid arthritis (RA).ObjectivesThis study aimed to compare the cost-effectiveness of well-established RA therapies using a claims-based algorithm in RA patients.MethodsAn electronic medical record (EMR) database from Zhujiang Hospital was utilized to estimate the cost-effectiveness of medication for RA patients, including IGU with MTX, biological DMARDs (bDMARDs) with MTX, and MTX alone for more than 6 months from 2014 to 2020. Patients who were deemed effective must meet all the following criteria according to the algorithm, high adherence; no bDMARDs or IGU switch or addition; no prescription of new csDMARDs; no increase in dose or frequency of index drug; no new use of chronic glucocorticoids or increase in glucocorticoid dose; and no more than one glucocorticoid injection. Average cost was calculated by summing total cost of effective treatment and dividing by number of patients achieving efficacy in each group.ResultsA total of 263 patients were included in the analysis. Based on a claims-based algorithm, the effective rate was 27.1 % (26/96) for IGU with MTX group, 11.2% (7/62) for bDMARDs with MTX group, and 13.3% (14/105) for MTX alone group, respectively. Average cost of effective treatment was $833.46 for IGU with MTX therapy, $2554.57 for bDMARDs with MTX therapy, and $171.48 for MTX alone (Table 1).Table 1.Effectiveness and Cost per Effectively Treated Patient with RACriteriaAll patients (n=263)IGU with MTX group(n=96)bDMARDs with MTX group (n=62)MTX (n=105)Effectiveness:no. of patients (%)a47(17.87%)26 (27.1%)7 (11.2/%)14 (13.3%)Cost of all RA-related medication per effectively treated patient(SD)$892.75(911.57)$833.46 (252.67)$2554.5 (1273.13)$171.4 (110.33)Average cost of all RA medications postindex (excluding biologic DMARDs) per patient (SD)b$146.38(114.60)$148.81 (123.12)$86.90 (74.53)$171.4 (110.33)Average cost of only biologicDMARDs postindex per patient (SD)b$746.38(926.35)$684.27(188.67)$2468.67(1285.91)/a χ2showed significant difference in percentage effectiveness for the original algorithm (p<0.05).bMedication cost was 2020 U.S. dollars.ConclusionIGU with MTX therapy was revealed to be both effective and modestly priced, which seemed to be a cost-effective strategy for RA therapy and warranted further cost-effectiveness investigation.References[1](2018) [2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis]. Zhonghua Nei Ke Za Zhi 57 (4), 242-251. https://doi.org/10.3760/cma.j.issn.0578-1426.2018.04.004[2]Hitchon, C. A., & El-Gabalawy, H. S. (2011). The synovium in rheumatoid arthritis. The open rheumatology journal, 5, 107–114. https://doi.org/10.2174/1874312901105010107[3]Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., Aletaha, D., Aringer, M., Askling, J., Balsa, A., Boers, M., den Broeder, A. A., Buch, M. H., Buttgereit, F., Caporali, R., Cardiel, M. H., … van der Heijde, D. (2020). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the rheumatic diseases, 79(6), 685–699. https://doi.org/10.1136/annrheumdis-2019-216655[4]Fraenkel, L., Bathon, J. M., England, B. R., St Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., Kremer, J., Nakamura, M. C., Russell, L. A., Singh, J. A., Smith, B. J., Sparks, J. A., Venkatachalam, S., Weinblatt, M. E., Al-Gibbawi, M., Baker, J. F., … Akl, E. A. (2021). 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis care & research, 73(7), 924–939. https://doi.org/10.1002/acr.24596Disclosure of InterestsNone declared
Collapse
|
195
|
Abdallah MS, Aboona BE, Adam J, Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal I, Aggarwal MM, Ahammed Z, Alekseev I, Anderson DM, Aparin A, Aschenauer EC, Ashraf MU, Atetalla FG, Attri A, Averichev GS, Bairathi V, Baker W, Ball Cap JG, Barish K, Behera A, Bellwied R, Bhagat P, Bhasin A, Bielcik J, Bielcikova J, Bordyuzhin IG, Brandenburg JD, Brandin AV, Bunzarov I, Cai XZ, Caines H, Calderón de la Barca Sánchez M, Cebra D, Chakaberia I, Chaloupka P, Chan BK, Chang FH, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chattopadhyay S, Chen D, Chen J, Chen JH, Chen X, Chen Z, Cheng J, Chevalier M, Choudhury S, Christie W, Chu X, Crawford HJ, Csanád M, Daugherity M, Dedovich TG, Deppner IM, Derevschikov AA, Dhamija A, Di Carlo L, Didenko L, Dixit P, Dong X, Drachenberg JL, Duckworth E, Dunlop JC, Elsey N, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fawzi FM, Fazio S, Federic P, Fedorisin J, Feng CJ, Feng Y, Filip P, Finch E, Fisyak Y, Francisco A, Fu C, Fulek L, Gagliardi CA, Galatyuk T, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Gupta A, Guryn W, Hamad AI, Hamed A, Han Y, Harabasz S, Harasty MD, Harris JW, Harrison H, He S, He W, He XH, He Y, Heppelmann S, Heppelmann S, Herrmann N, Hoffman E, Holub L, Hu Y, Huang H, Huang HZ, Huang SL, Huang T, Huang X, Huang Y, Humanic TJ, Igo G, Isenhower D, Jacobs WW, Jena C, Jentsch A, Ji Y, Jia J, Jiang K, Ju X, Judd EG, Kabana S, Kabir ML, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Khyzhniak YV, Kikoła DP, Kim C, Kimelman B, Kincses D, Kisel I, Kiselev A, Knospe AG, Ko HS, Kochenda L, Kosarzewski LK, Kramarik L, Kravtsov P, Kumar L, Kumar S, Kunnawalkam Elayavalli R, Kwasizur JH, Lacey R, Lan S, Landgraf JM, Lauret J, Lebedev A, Lednicky R, Lee JH, Leung YH, Lewis N, Li C, Li C, Li W, Li X, Li Y, Liang X, Liang Y, Licenik R, Lin T, Lin Y, Lisa MA, Liu F, Liu H, Liu H, Liu P, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Longacre RS, Loyd E, Lukow NS, Luo XF, Ma L, Ma R, Ma YG, Magdy N, Mallick D, Margetis S, Markert C, Matis HS, Mazer JA, Minaev NG, Mioduszewski S, Mohanty B, Mondal MM, Mooney I, Morozov DA, Mukherjee A, Nagy M, Nam JD, Nasim M, Nayak K, Neff D, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nishitani R, Nogach LV, Nonaka T, Nunes AS, Odyniec G, Ogawa A, Oh S, Okorokov VA, Page BS, Pak R, Pan J, Pandav A, Pandey AK, Panebratsev Y, Parfenov P, Pawlik B, Pawlowska D, Perkins C, Pinsky L, Pluta J, Pokhrel BR, Ponimatkin G, Porter J, Posik M, Prozorova V, Pruthi NK, Przybycien M, Putschke J, Qiu H, Quintero A, Racz C, Radhakrishnan SK, Raha N, Ray RL, Reed R, Ritter HG, Robotkova M, Rogachevskiy OV, Romero JL, Roy D, Ruan L, Rusnak J, Sahoo AK, Sahoo NR, Sako H, Salur S, Sandweiss J, Sato S, Schmidke WB, Schmitz N, Schweid BR, Seck F, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Shao T, Sheikh AI, Shen DY, Shi SS, Shi Y, Shou QY, Sichtermann EP, Sikora R, Simko M, Singh J, Singha S, Skoby MJ, Smirnov N, Söhngen Y, Solyst W, Song Y, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stefaniak M, Stewart DJ, Strikhanov M, Stringfellow B, Suaide AAP, Sumbera M, Summa B, Sun XM, Sun X, Sun Y, Sun Y, Surrow B, Svirida DN, Sweger ZW, Szymanski P, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Todoroki T, Tokarev M, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Truhlar T, Trzeciak BA, Tsai OD, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vasiliev AN, Vassiliev I, Verkest V, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang JS, Wang P, Wang X, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu J, Wu J, Wu Y, Xi B, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu Y, Xu Z, Xu Z, Yan G, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yu Y, Zbroszczyk H, Zha W, Zhang C, Zhang D, Zhang J, Zhang S, Zhang S, Zhang XP, Zhang Y, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao J, Zhou C, Zhou Y, Zhu X, Zurek M, Zyzak M. Measurements of Proton High-Order Cumulants in sqrt[s_{NN}]=3 GeV Au+Au Collisions and Implications for the QCD Critical Point. PHYSICAL REVIEW LETTERS 2022; 128:202303. [PMID: 35657878 DOI: 10.1103/physrevlett.128.202303] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 04/11/2022] [Indexed: 06/15/2023]
Abstract
We report cumulants of the proton multiplicity distribution from dedicated fixed-target Au+Au collisions at sqrt[s_{NN}]=3.0 GeV, measured by the STAR experiment in the kinematic acceptance of rapidity (y) and transverse momentum (p_{T}) within -0.5<y<0 and 0.4<p_{T}<2.0 GeV/c. In the most central 0%-5% collisions, a proton cumulant ratio is measured to be C_{4}/C_{2}=-0.85±0.09 (stat)±0.82 (syst), which is 2σ below the Poisson baseline with respect to both the statistical and systematic uncertainties. The hadronic transport UrQMD model reproduces our C_{4}/C_{2} in the measured acceptance. Compared to higher energy results and the transport model calculations, the suppression in C_{4}/C_{2} is consistent with fluctuations driven by baryon number conservation and indicates an energy regime dominated by hadronic interactions. These data imply that the QCD critical region, if created in heavy-ion collisions, could only exist at energies higher than 3 GeV.
Collapse
|
196
|
Abdallah MS, Aboona BE, Adam J, Adamczyk L, Adams JR, Adkins JK, Agakishiev G, Aggarwal I, Aggarwal MM, Ahammed Z, Alekseev I, Anderson DM, Aparin A, Aschenauer EC, Ashraf MU, Atetalla FG, Attri A, Averichev GS, Bairathi V, Baker W, Ball Cap JG, Barish K, Behera A, Bellwied R, Bhagat P, Bhasin A, Bielcik J, Bielcikova J, Bordyuzhin IG, Brandenburg JD, Brandin AV, Bunzarov I, Cai XZ, Caines H, Calderón de la Barca Sánchez M, Cebra D, Chakaberia I, Chaloupka P, Chan BK, Chang FH, Chang Z, Chankova-Bunzarova N, Chatterjee A, Chattopadhyay S, Chen D, Chen J, Chen JH, Chen X, Chen Z, Cheng J, Chevalier M, Choudhury S, Christie W, Chu X, Crawford HJ, Csanád M, Daugherity M, Dedovich TG, Deppner IM, Derevschikov AA, Dhamija A, Di Carlo L, Didenko L, Dixit P, Dong X, Drachenberg JL, Duckworth E, Dunlop JC, Elsey N, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fawzi FM, Fazio S, Federic P, Fedorisin J, Feng CJ, Feng Y, Filip P, Finch E, Fisyak Y, Francisco A, Fu C, Fulek L, Gagliardi CA, Galatyuk T, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Gupta A, Guryn W, Hamad AI, Hamed A, Han Y, Harabasz S, Harasty MD, Harris JW, Harrison H, He S, He W, He XH, He Y, Heppelmann S, Heppelmann S, Herrmann N, Hoffman E, Holub L, Hu Y, Huang H, Huang HZ, Huang SL, Huang T, Huang X, Huang Y, Humanic TJ, Igo G, Isenhower D, Jacobs WW, Jena C, Jentsch A, Ji Y, Jia J, Jiang K, Ju X, Judd EG, Kabana S, Kabir ML, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Khyzhniak YV, Kikoła DP, Kim C, Kimelman B, Kincses D, Kisel I, Kiselev A, Knospe AG, Ko HS, Kochenda L, Kosarzewski LK, Kramarik L, Kravtsov P, Kumar L, Kumar S, Kunnawalkam Elayavalli R, Kwasizur JH, Lacey R, Lan S, Landgraf JM, Lauret J, Lebedev A, Lednicky R, Lee JH, Leung YH, Lewis N, Li C, Li C, Li W, Li X, Li Y, Liang X, Liang Y, Licenik R, Lin T, Lin Y, Lisa MA, Liu F, Liu H, Liu H, Liu P, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Longacre RS, Loyd E, Lukow NS, Luo XF, Ma L, Ma R, Ma YG, Magdy N, Mallick D, Margetis S, Markert C, Matis HS, Mazer JA, Minaev NG, Mioduszewski S, Mohanty B, Mondal MM, Mooney I, Morozov DA, Mukherjee A, Nagy M, Nam JD, Nasim M, Nayak K, Neff D, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nishitani R, Nogach LV, Nonaka T, Nunes AS, Odyniec G, Ogawa A, Oh S, Okorokov VA, Page BS, Pak R, Pan J, Pandav A, Pandey AK, Panebratsev Y, Parfenov P, Pawlik B, Pawlowska D, Perkins C, Pinsky L, Pintér RL, Pluta J, Pokhrel BR, Ponimatkin G, Porter J, Posik M, Prozorova V, Pruthi NK, Przybycien M, Putschke J, Qiu H, Quintero A, Racz C, Radhakrishnan SK, Raha N, Ray RL, Reed R, Ritter HG, Robotkova M, Rogachevskiy OV, Romero JL, Roy D, Ruan L, Rusnak J, Sahoo AK, Sahoo NR, Sako H, Salur S, Sandweiss J, Sato S, Schmidke WB, Schmitz N, Schweid BR, Seck F, Seger J, Sergeeva M, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Shao T, Sheikh AI, Shen DY, Shi SS, Shi Y, Shou QY, Sichtermann EP, Sikora R, Simko M, Singh J, Singha S, Skoby MJ, Smirnov N, Söhngen Y, Solyst W, Sorensen P, Spinka HM, Srivastava B, Stanislaus TDS, Stefaniak M, Stewart DJ, Strikhanov M, Stringfellow B, Suaide AAP, Sumbera M, Summa B, Sun XM, Sun X, Sun Y, Sun Y, Surrow B, Svirida DN, Sweger ZW, Szymanski P, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Todoroki T, Tokarev M, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tripathy SK, Truhlar T, Trzeciak BA, Tsai OD, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vasiliev AN, Vassiliev I, Verkest V, Videbaek F, Vokal S, Voloshin SA, Wang F, Wang G, Wang JS, Wang P, Wang X, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Wen L, Westfall GD, Wieman H, Wissink SW, Witt R, Wu J, Wu J, Wu Y, Xi B, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu Y, Xu Z, Xu Z, Yan G, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yu Y, Zbroszczyk H, Zha W, Zhang C, Zhang D, Zhang J, Zhang S, Zhang S, Zhang XP, Zhang Y, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao J, Zhou C, Zhou Y, Zhu X, Zurek M, Zyzak M. Measurements of _{Λ}^{3}H and _{Λ}^{4}H Lifetimes and Yields in Au+Au Collisions in the High Baryon Density Region. PHYSICAL REVIEW LETTERS 2022; 128:202301. [PMID: 35657899 DOI: 10.1103/physrevlett.128.202301] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 01/26/2022] [Accepted: 04/05/2022] [Indexed: 06/15/2023]
Abstract
We report precision measurements of hypernuclei _{Λ}^{3}H and _{Λ}^{4}H lifetimes obtained from Au+Au collisions at sqrt[s_{NN}]=3.0 GeV and 7.2 GeV collected by the STAR experiment at the Relativistic Heavy Ion Collider, and the first measurement of _{Λ}^{3}H and _{Λ}^{4}H midrapidity yields in Au+Au collisions at sqrt[s_{NN}]=3.0 GeV. _{Λ}^{3}H and _{Λ}^{4}H, being the two simplest bound states composed of hyperons and nucleons, are cornerstones in the field of hypernuclear physics. Their lifetimes are measured to be 221±15(stat)±19(syst) ps for _{Λ}^{3}H and 218±6(stat)±13(syst) ps for _{Λ}^{4}H. The p_{T}-integrated yields of _{Λ}^{3}H and _{Λ}^{4}H are presented in different centrality and rapidity intervals. It is observed that the shape of the rapidity distribution of _{Λ}^{4}H is different for 0%-10% and 10%-50% centrality collisions. Thermal model calculations, using the canonical ensemble for strangeness, describes the _{Λ}^{3}H yield well, while underestimating the _{Λ}^{4}H yield. Transport models, combining baryonic mean-field and coalescence (jam) or utilizing dynamical cluster formation via baryonic interactions (phqmd) for light nuclei and hypernuclei production, approximately describe the measured _{Λ}^{3}H and _{Λ}^{4}H yields. Our measurements provide means to precisely assess our understanding of the fundamental baryonic interactions with strange quarks, which can impact our understanding of more complicated systems involving hyperons, such as the interior of neutron stars or exotic hypernuclei.
Collapse
|
197
|
Wu J, Nadarajah R, Raveendra K, Cowan JC, Gale CP. FIND-AF: a widely applicable artificial intelligence algorithm to target systematic screening for atrial fibrillation in older individuals through primary care electronic health records. Europace 2022. [DOI: 10.1093/europace/euac053.565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Foundation. Main funding source(s): British Heart Foundation
Background
Systematic screening for atrial fibrillation (AF) in people ≥75 years of age can improve detection rates, anticoagulant prescription and clinical outcomes but is inefficient.(1) A large proportion of European populations are registered in primary care with a routinely-collected electronic health record (EHR).(2) An algorithm embedded in this system to identify people at higher risk of incident AF could facilitate targeted AF screening.
Purpose
To develop and internally validate a widely-applicable artificial intelligence (AI) algorithm for predicting incident AF in people ≥75 years of age using primary care EHRs.
Methods
We identified people who were ≥75 years of age (1998 – 2018), in the nationwide Clinical Practice Research Datalink (CPRD)-GOLD primary care EHR dataset and followed them until a diagnosis of AF, or withdrawal from CPRD, or 6 months. Each subject had 81 features including age, sex, ethnicity and comorbidities. Algorithms developed with random forest (RF) and multivariable logistic regression (MLR), were compared by area under receiver operating curve (AUROC) and the proportion of patient EHRs to which the algorithms could be applied
Results
440,000 patients were studied, with 3922 occurrences of AF. The RF algorithm achieved an AUROC of 0.77 after 10 fold cross-validation, 12% better than the MLR algorithm (0.68). Notably the RF algorithm could be applied to all EHRs. At 75% sensitivity, the RF algorithm would reduce the potential number needed to screen for one new case of AF to 11, an improvement of over 6-fold compared to using age alone.
Conclusions
This study showed a novel AI algorithm that can be widely applied in nationwide European primary care EHRs to target screening for AF in a population that derives clinical benefit.
Collapse
|
198
|
Ma M, Xia L, Chen X, Yin Y, Wu J, Qiu L. M266 Establishment of biological variation and age-related reference interval model of 22 common biochemical analytes in elderly through real world big data mining. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
199
|
Wu J, Heger C. Gene Editing/Gene Therapies: Late Breaking Abstract: RAPID QUANTIFICATION OF CAPSID CONTENT OF ADENO-ASSOCIATED VIRUSES (AAVS) BY CAPILLARY ELECTROPHORESIS-BASED WESTERN ANALYSIS. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00388-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
200
|
Atlas I, Wu J, Shocron A, Suss M. Spatial variations of pH in electrodialysis stacks: Theory. Electrochim Acta 2022. [DOI: 10.1016/j.electacta.2022.140151] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|